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Approximately 50 000 people undergo hemato-poietic cell transplantation (HCT) worldwide each year. Advances in transplantation tech-
niques and supportive care practices have led to pro-
gressive improvements in survival for HCT recipients. 
As patients survive long-term after transplantation, 
they are at risk for developing late complications related 
to pre-, peri- and posttransplantation exposures. These 
complications can cause substantial morbidity, impair 
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For wider dissemination, the guidelines for “Recommended Screening and Preventive Practices For Long-Term Survivors after Hematopoietic-
Cell Transplantation” are being co-published in the following journals: Biology of Blood and Marrow Transplantation, Bone Marrow 
Transplantation, Hematology/Oncology and Stem Cell Therapy and Revista Brasileira de Hematologia e Hemoterapia.
advances in hematopoietic cell transplantation (hCt) technology and supportive care techniques have 
led to improvements in long-term survival after hCt. Emerging indications for transplantation, introduc-
tion of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less in-
tense conditioning regimens have also contributed to an increase in the number of hCt survivors. these 
survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation 
exposures and risk factors. Guidelines for screening and preventive practices for hCt survivors were 
published in 2006. an international group of transplantation experts was convened in 2011 to review 
contemporary literature and update the recommendations while considering the changing practice of 
transplantation and international applicability of these guidelines. this review provides the updated 
recommendations for screening and preventive practices for pediatric and adult survivors of autologous 
and allogeneic hCt. 
quality of life and can contribute to late mortality in 
HCT recipients. Several studies have shown that the 
life expectancy of HCT survivors is lower than expect-
ed at 10 to 30 years posttransplantation and secondary 
cancers, infections and organ dysfunction are common 
causes of late deaths in this population.1-6 
 Recognizing the need for guidance about appro-
priate systematic long-term follow-up of HCT survi-
vors, the Center for International Blood and Marrow 
special report laTe eFFeCTS guidelineS FOr HCT SurvivOrS 
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com2
Transplant Research (CIBMTR), the European 
Group for Blood and Marrow Transplantation 
(EBMT), and the American Society for Blood and 
Marrow Transplantation (ASBMT) convened a 
group of experts in 2006 and provided consen-
sus recommendations for screening and preventive 
practices for autologous and allogeneic HCT survi-
vors.7,8 To update these previous guidelines, the in-
ternational working group was reconvened in 2011 
to review the prevailing literature on late effects of 
transplantation and to suggest revised guidelines, if 
applicable. To ensure international applicability, the 
working group included participants from the Asia-
Pacific Blood and Marrow Transplantation Group 
(APBMT), the Bone Marrow Transplant Society of 
Australia and New Zealand (BMTSANZ), the East 
Mediterranean Blood and Marrow Transplantation 
Group (EMBMT) and Sociedade Brasileira de 
Transplante de Medula Ossea (SBTMO).
 The proposed guidelines focus on risks faced by 
children and adults who have survived 6 months or 
more following transplantation and address autolo-
gous and allogeneic HCT recipients. Since long-term 
HCT recipients may no longer be under the care of 
transplant centers and may have returned to the care 
of community health care providers, the guidelines 
are geared towards providers who routinely care for 
HCT recipients as well as those who do not. 
 The working group recognized the general lack 
of clinical trials focused on screening and preven-
tive practices among HCT recipients and the need 
for more research in this area. Hence, many of these 
recommendations are not based on evidence derived 
from randomized or other controlled trials, but are 
supported by retrospective studies that have identi-
fied specific complications in long-term survivors 
and their associated risk factors. When such studies 
are not available, the guidelines are based on knowl-
edge derived from non-transplant patients as well as 
on the consensus opinion of the working group par-
ticipants. Taking into account the risks and potential 
consequences of late complications, they represent 
sensible practices to optimize outcomes. The recom-
mendations should not be interpreted as mandatory 
for all recipients; good medical practice and judgment 
dictate that certain recommendations may not be ap-
plicable or may even be contraindicated in individual 
patients or groups of patients. 
 It was also recognized that the practice of HCT 
is continuously changing. Some examples of such 
changes include emerging indications for transplanta-
tion (eg, autoimmune diseases, sickle cell disease), in-
creased utilization of newer donor sources (eg, umbil-
ical cord blood and haploidentical donors), decreased 
use of total body irradiation (TBI) for conditioning 
and evaluation of novel therapies as part of HCT (eg, 
posttransplant maintenance therapy in myeloma). 
With the advent of non-myeloablative and reduced 
intensity conditioning (NMA/RIC) regimens, a larg-
er number of older patients now receive transplanta-
tion. The risks and constellation of late complications 
may change as newer practices in transplantation be-
come more prevalent. Providers should be cognizant 
of any unique exposures and risks associated with 
these practices (eg, delayed immune reconstitution in 
umbilical cord blood recipients) when considering a 
long-term follow-up care plan for their patients. 
 A broad constellation of medical issues faced by 
late survivors of transplantation is presented. Most 
of the late complications discussed here pertain par-
ticularly to allogeneic recipients. However, autolo-
gous recipients are at risk for many of the same late 
complications and may experience unusual toxicity or 
immune impairment following transplantation that 
places them at risk similar to allogeneic recipients 
(eg, exposure to prolonged corticosteroids or other 
drugs that may cause prolonged lymphopenia post-
transplantation). Therefore, although some of the 
following recommendations do not generally apply to 
autologous recipients, providers should remain alert 
to these complications in all patients. 
 The guidelines are summarized in Tables 1 and 
2. The Appendix includes tables that highlight rec-
ommendations for posttransplant immunizations 
(Appendix Table A) and recommendations by se-
lected exposures/risk factors (TBI, chronic GVHD, 
pediatric recipients) (Appendix Table B). Appendix 
Table C lists other guidelines that have been refer-
enced in this manuscript along with current links 
to their website. Readers can also refer to guidelines 
developed by the Children’s Oncology Group for fol-
low-up for pediatric cancer survivors, which include 
information on pediatric HCT recipients (www.sur-
vivorshipguidelines.org). Representative references 
are included in this document to guide readers who 
would like more information on individual topics. 
 The National Marrow Donor Program (NMDP) 
publishes a patient version of the follow-up guide-
lines (www.BeTheMatch.org/Patient); we recom-
mend that patients use these guidelines to establish 
a long-term follow-up care plan in consultation with 
their health care provider based on their individual 
exposures and risk factors. The NMDP also makes 
a summary of the guidelines available for physicians 
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Table 1. Summary recommendations for screening and prevention of late complications in long-term HCT survivors.
Tissues/organs Late Complications General Risk Factors Monitoring Tests Monitoring Tests and Preventive Measures In All HCT Recipients
Monitoring Tests and Preventive Measures In Special 
Populations
immune 
system
- infections - donor source
- Hla disparity
- T-cell depletion
- gvHd
-  Prolonged immuno-
suppression
-  venous access 
devices
-  CMv antigen 
or PCr in 
patients at high 
risk for CMv 
reactivation 
-  PCP prophylaxis for initial 6 
months after HCT
-  immunizations posttransplant 
according to published guidelines
-  administration of antibiotics 
for endocarditis prophylaxis 
according to american Heart 
association guidelines
-  Patients with cgvHd: antimicrobial prophylaxis 
targeting encapsulated organisms and PCP for the 
duration of immunosuppressive therapy 
-  Patients with cgvHd: Screening for CMv reactivation 
should be based on risk factors, including intensity of 
immunosuppression.
Ocular - Cataracts
- Sicca syndrome
-  Microvascular 
retinopathy
-  TBi/radiation exposure 
to head and neck 
- Corticosteroids
- gvHd
-  Ophthalmologic 
exam
-  routine clinical evaluation at 6 
months and 1 year after HCT and 
at least yearly thereafter
-  Ophthalmologic examination with 
measurement of visual acuity and 
fundus examination at 1 year after 
HCT, subsequent evaluation based 
on findings and risk factors 
-  Prompt ophthalmologic 
examination in patients with visual 
symptoms
-  Patients with cgvHd: routine clinical evaluation, and if 
indicated, ophthalmologic examination more frequently
Oral - Sicca syndrome
- Caries
- gvHd
-  TBi/radiation exposure 
to head and neck 
-  dental 
assessment
-  education about preventive oral 
health practices
-  Clinical oral assessment at 6 
months and 1 year after HCT and 
at least yearly thereafter with 
particular attention to intra-oral 
malignancy evaluation
-  dental assessment at 1 year 
after HCT and then at least yearly 
thereafter 
-  Pediatric recipients: Yearly assessment of teeth 
development
-  Patients with cgvHd: Consider more frequent oral and 
dental assesments with particular attention to intra-oral 
malignancy evaluation
respiratory -  idiopathic 
pneumonia 
syndrome
-  Bronchiolitis 
obliterans 
syndrome
-  Cryptogenic 
organizing 
pneumonia
-  Sino-pulmonary 
infections 
-  TBi/radiation exposure 
to chest
- gvHd
-  infectious agents
-  allogeneic HCT
- Busulfan exposure
- PFT’s
-  radiologic 
studies (e.g. 
chest X-ray, CT 
scan)
-  routine clinical evaluation at 6 
months and 1 year after HCT and 
at least yearly thereafter
-  assessment of tobacco use and 
couselling against smoking 
-  PFT’s and focused radiologic 
assessment for allogeneic HCT 
recipients with symptoms or signs 
of lung compromise
-  Patients with cgvHd: Some experts recommend earlier 
and more frequent clinical evaluation and PFT’s
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Table 1 (cont). Summary recommendations for screening and prevention of late complications in long-term HCT survivors.
Tissues/organs Late Complications General Risk Factors Monitoring Tests Monitoring Tests and Preventive Measures In All HCT Recipients
Monitoring Tests and Preventive Measures In Special 
Populations
Cardiac and 
vascular
- Cardiomyopathy
-  Congestive heart 
failure
- arrhythmias
- valvular anomaly
-  Coronary artery 
disease
-  Cerebrovascular 
disease
-  Peripheral 
arterial disease
- anthracycline exposure
-  TBi/radiation exposure 
to neck or chest
- Older age at HCT
- allogeneic HCT
-  Cardiovascular risk-
factors before/after HCT 
-  Chronic kidney disease
- Metabolic syndrome
-  Cumulative dose 
of anthracyclines
-  echocardiogram 
with ventricular 
function, eCg 
in patients 
at risk and in 
symptomatic 
patients
-  Fasting lipid 
profile (including 
Hdl-C, ldl-C 
and triglycerides)
-  Fasting blood 
sugar
-  routine clinical assessment of 
cardiovascular risk factors as per 
general health maintenance at 1 
year and at least yearly thereafter
-  education and counseling on 
“heart“ healthy lifestyle (regular 
exercise, healthy weight, no 
smoking, dietary counseling)
-  early treatment of cardiovascular 
risk factors such as diabetes, 
hypertension and dyslipidemia
-  administration of antibiotics 
for endocarditis prophylaxis 
according to american Heart 
association guidelines
liver - gvHd
- Hepatitis B
- Hepatitis C
- iron overload
-  Cumulative transfusion 
exposure
-  risk factors for viral 
hepatitis transmission
- lFT’s
- liver biopsy
- Serum ferritin
-  imaging for iron 
overload (Mri or 
SQuid)
-  lFT’s every 3-6 months in the first 
year, then individualized, but at 
least yearly thereafter
-  Monitor viral load by PCr for 
patients with known hepatitis B or 
C, with liver and infectious disease 
specialist consultation
-  Consider liver biopsy at 8-10 years 
after HCT to assess cirrhosis 
in patients with chronic HCv 
infection 
-  Serum ferritin at 1  year after HCT 
in patients who have received 
rBC transfusions; consider 
liver biopsy or imaging study 
for abnormal results based on 
magnitude of elevation and clinical 
context; subsequent monitoring 
is suggested for patients with 
elevated lFT’s, continued rBC 
transfusions, or presence of HCv 
infection
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Table 1 (cont). Summary recommendations for screening and prevention of late complications in long-term HCT survivors.
Tissues/
organs Late Complications General Risk Factors Monitoring Tests
Monitoring Tests and Preventive 
Measures In All HCT Recipients
Monitoring Tests and Preventive Measures In Special 
Populations
renal and 
genitourinary
-  Chronic kidney 
disease
-  Bladder dysfunction
-  urinary tract 
infections
- TBi
-  drug exposure (e.g. 
calcineurin inhibitors, 
amphotericin, 
aminoglycosides)
- CMv
- Hemorrhagic cystitis
- urine protein
-  Serum 
creatinine
- Bun
-  Blood pressure assessment at 
every clinic visit, with aggressive 
hypertension management
-  assess renal function with Bun, 
creatinine and urine protein at 6 
months, 1 year and at least yearly 
thereafter
-  Consider further workup (kidney 
biopsy or renal ultrasound) 
for for further workup of renal 
dysfunction as clinically indicated
Muscle and 
connective 
tissue
- Myopathy
- Fascitis/ scleroderma
- Polymyositis
- Corticosteroids
- gvHd
-  evaluate ability 
to stand from a 
sitting position
-  Clinical 
evaluation of 
joint range of 
motion
-  Follow general population 
guidelines for physical activity
-  Frequent clinical evaluation 
for myopathy in patients on 
corticosteroids
-  Patients with cgvHd: Physical therapy consultation 
in patients with prolonged corticosteroid exposure, 
fascitis or scleroderma
-  Patients with cgvHd: Frequent clinical evaluation 
by manual muscle tests or by assessing ability to 
go from sitting to standing position for patients on 
prolonged corticosteroids
Skeletal -  Osteopenia/ 
osteoporosis
-  avascular necrosis
- inactivity
- TBi
- Corticosteroids
- gvHd
- Hypogonadism
- allogeneic HCT
-  dual photon 
densitometry
-  Mri to evaluate 
patients with 
joint symptoms 
-  dual photon densitometry at 
1  year for adult women, all 
allogeneic HCT recipients and 
patients who are at high risk for 
bone loss; subsequent testing 
determined by defects or to 
assess response to therapy
-  Physical activity, vitamin d and 
calcium supplementation to 
prevent loss of bone density
-  Patients with cgvHd: Consider dual photon 
densitometry at an earlier date in patients with 
prolonged corticosteroid or calcineurin inhibitor 
exposure. 
nervous 
system
- leukoencephalopathy
- late infections
-  neuropsychological 
and cognitive deficits
-  Calcineurin 
neurotoxicity
-  Peripheral neuropathy
-  TBi/radiation exposure 
to head
-  gvHd
- exposure to fludarabine
-  intrathecal 
chemotherapy
-  Clinical evaluation for symptoms 
and signs of neurologic 
dysfunction at 1 year and yearly 
thereafter 
-  diagnostic testing (e.g., 
radiographs, nerve conduction 
studies) for those with symptoms 
or signs
-  Pediatric recipients: annual assessment for 
congnitive development milestones
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Table 1 (cont). Summary recommendations for screening and prevention of late complications in long-term HCT survivors.
Tissues/
organs Late Complications General Risk Factors Monitoring Tests
Monitoring Tests and Preventive 
Measures In All HCT Recipients
Monitoring Tests and Preventive Measures In Special 
Populations
endocrine - Hypothyroidism
- Hypoadrenalism
- Hypogonadism
- growth retardation
-  TBi/radiation exposure 
(e.g. head and neck, 
CnS)
- Corticosteroids
- Young age at HCT
-  Chemotherapy 
exposure 
-  Thyroid function 
tests
-  FSH, lH, 
testosterone
-  growth velocity 
in children
-  Thyroid function testing yearly 
post-HCT, or if relevant symptoms 
develop
-  Clinical and endocrinologic 
gonadal assessment for post-
pubertal women at 1 year, 
subsequent followup based on 
menopausal status
-  gonadal function in men, including 
FSH, lH and testosterone, should 
be assessed as warranted by 
symptoms
-  Pediatric recipients: Clinical and endocrinologic 
gonadal assessment for pre-pubertal boys and girls 
within 1 year of transplant, with further followup 
as determined in consultation with a pediatric 
endocrinologist
-  Pediatric recipients: Monitor growth velocity in 
children annually; assessment of thyroid, and growth 
hormone function if clinically indicated  
-  Patients with cgvHd: Slow terminal tapering of 
corticosteroids for those with prolonged exposure
-  Patients with cgvHd: Consider stress doses of 
corticosteroids during acute illness for patients who 
have received chronic corticosteroids
Mucocuta-
neous
- Cutaneous sclerosis
- genital gvHd
- gvHd
-  TBi/radiation exposure 
to pelvis
- Pelvic exam -  Counsel patients to perform 
routine self exam of skin and avoid 
excessive exposure to sunlight 
without adequate protection
-  annual gynecologic exam 
in women to detect early 
involvement of vaginal mucosa 
by gvHd
-  Patients with cgvHd and TBi recipients: Consider 
more frequent gynecologic evaluation based on 
clinical symptoms 
Second 
cancers
- Solid tumors
-  Hematologic 
malignancies
- PTld
- gvHd
- TBi/radiation exposure
- T-cell depletion
-  exposure to alkylating 
agents or etoposide  
- Mammogram
-  Screening 
for colon 
cancer (e.g. 
colonscopy, 
sigmoidoscopy, 
fecal occult 
blood testing)
- Pap smear
-  Counsel patients about risks of 
secondary malignancies annually 
and encourage them to perform 
self exam (e.g. skin, testicles/
genitalia)
-  Counsel patients to avoid high risk 
behaviors (e.g. smoking)
-  Follow general population 
recommendations for cancer 
screening
-  Patients with cgvHd: Clinical and dental evaluation 
with particular attention towards oral and pharyngeal 
cancer
-  TBi and chest irradiation recipients: Screening 
mammography in women starting at age 25 or 8 years 
after radiation exposure, whichever occurs later but 
no later than age 40
special report
laTe eFFeCTS guidelineS FOr HCT SurvivOrS
Hem
atol Oncol Stem
 Cell Ther 5(1)     First Quarter 2012 
hem
oncstem
.edm
gr.com
7
Table 1 (cont). Summary recommendations for screening and prevention of late complications in long-term HCT survivors.
Tissues/
organs Late Complications General Risk Factors Monitoring Tests
Monitoring Tests and Preventive Measures 
In All HCT Recipients
Monitoring Tests and Preventive Measures In 
Special Populations
Psychosocial 
and sexual
- depression
- anxiety
- Fatigue
- Sexual dysfunction 
-  Prior psychiatric 
morbidity 
- Hypogonadism
-  Psychological 
evaluation
-  Clinical assessment throughout 
recovery period, at 6 months, 1 year and 
annually thereafter, with mental health 
professional counseling recommended 
for those with recognized deficits
-  encouragement of robust support 
networks
-  regularly assess level of spousal/
caregiver psychological adjustment and 
family functioning
-  Query adults about sexual function at 
6 months, 1  year and at least annually 
thereafter
Fertility - infertility - TBi/radiation exposure
-  Chemotherapy 
exposure
- FSH, lH levels -  Consider referral to appropriate 
specialists for patients who are 
contemplating a  pregnancy or are 
having difficulty conceiving
-  Counsel sexually active patients in the 
reproductive age group about birth 
control post-HCT
general 
health
-  recommended screening as per general 
population (see text)
HCT indicates hematopoietic cell transplantation; cgvHd, chronic graft-versus-host disease; CMv, cytomegalovirus; PCr, polymerase chain reaction; PCP, Pneumocystis pneumonia; TBi, total body irradiation; PFT’s, pulmonary function tests; CT, computed 
tomography; eCg, electrocardiogram; lFT’s, liver function tests; Mri; magnetic resonance imaging; SQuid, superconducting quantum interference device; HCv, hepatitis C; rBC, red blood cell; Bun, blood urea nitrogen; CnS, central nervous system; FSH, 
follicle stimulating hormone; lH, luteinizing hormone; PTld, post-transplant lymphoproliferative disorder.
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Table 2. abbreviated summary recommendations for screening 
and prevention of late complications in long-term HCT survivors 
organized by time after transplantation.
Recommended 
Screening/
Prevention
6 month 1 year Annually
Immunity
   encapsulated 
   organism 
   prophylaxis
2 2 2
   PCP prophylaxis 1 2 2
   CMv testing 2 2 2
   immunizations 1 1 1
Ocular
   Ocular clinical 
   symptom 
   evaluation
1 1 1
   Ocular fundus 
   exam + 1 +
Oral Complications
   Clinical 
   assessment 1 1 1
   dental 
   assessment + 1 1
Respiratory
   Clinical pulmonary 
   assessment 1 1 1
   Smoking tobacco 
   avoidance 1 1 1
   Pulmonary 
   function testing + + +
   Chest radiography + + +
Cardiac and 
vascular
   Cardiovascular 
   risk-factor 
   assessment
+ 1 1
Liver
   liver function 
   testing 1 1 +
   Serum ferritin 
   testing 1 +
Kidney
   Blood pressure 
   screening 1 1 1
   urine protein 
   screening 1 1 1
   Bun/creatinine 
   testing 1 1 1
   Muscle and 
   connective tissue
   evaluation for 
   muscle weakness 2 2 2
   Physical activity 
   counseling 1 1 1
Skeletal
   Bone density 
   testing (adult 
   women, all  
   allogeneic 
   transplant 
   recipients and 
   patients at high 
   risk for bone loss)  
1 +
Nervous system
   neurologic  
   clinical evaluation + 1 1
   evaluate 
   for cognitive 
   development
1 1
Endocrine
   Thyroid function   
    testing 1 1
   growth velocity in 
   children 1 1
   gonadal function 
   assessment 
   (prepubertal men 
   and women)
1 1 1
   gonadal function 
   assessment 
   (postpubertal 
   women)
1 +
   gonadal function 
   assessment  
   (postpubertal 
   men)    
+ +
Mucocutaneous
   Skin self-exam
   and sun exposure 
   counseling 
1 1 1
   gynecologic exam 
   in women + 1 1
Second cancers
   Second 
   cancer vigilance 
   counseling
1 1
   Screening for 
   second cancers 1 1
Psychosocial
   Psychosocial/QOl 
   clinical 
   assessment
1 1 1
   Sexual function 
   assessment 1 1 1
1=recommended for all transplant recipients; 2=recommended for any patient with 
ongoing chronic gvHd or immunosuppression; +=reassessment recommended for 
abnormal testing in a previous time period or for new signs/symptoms.
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(online, mobile app, and in print at www.marrow.org/
md-guidelines). 
IMMUNITY AND INFECTIONS
International consensus guidelines for preventing in-
fectious complications among HCT recipients were 
published in 2009; these guidelines comprehensively 
address late infectious complications of transplanta-
tion and provide recommendations for vaccination 
of HCT recipients.9-11 Environmental risks, safe sex, 
water and food safety and travel safety among HCT 
recipients have also been covered by these guidelines. 
Patients who are immune compromised should be 
educated regarding their immune status and of the 
warning symptoms of infection and advised to seek 
early medical attention if they have symptoms. 
Infectious complications are frequent in the period 
soon after HCT because of cytopenias, immune ab-
lation and/or immunosuppression. Immune recon-
stitution occurs gradually over time (generally 12-18 
months) and is slower for allogeneic recipients, par-
ticularly those receiving umbilical cord blood, HLA-
mismatched or T-cell depleted grafts and in survivors 
with graft-versus-host disease (GVHD) or those 
who have received prolonged immunosuppression.12 
T-helper lymphocyte (CD4) counts and CD4/CD8 
ratios are good markers of immune reconstitution 
and some experts use these assessments as surrogate 
markers of the completeness of immune reconstitu-
tion to guide duration of viral or other infection pro-
phylaxis after HCT. 
Bacterial, fungal, and viral infections may occur 
months or years after transplantation in patients with 
delayed immune reconstitution. Although infectious 
risk is highest in the first 1-2 years after transplan-
tation, an increased risk of infection may continue 
long-term for some recipients of allogeneic trans-
plants, such as patients with chronic GVHD requir-
ing extended immunosuppressive therapy. In patients 
with chronic GVHD, opsonization is impaired, and 
encapsulated bacteria (N. meningitides, H. influen-
zae, and S. pneumonia) may cause rapidly progressive 
and life-threatening infection. Furthermore, patients 
may have undergone splenectomy for the treatment 
of their underlying disease or may be functionally 
asplenic secondary to GVHD or splenic irradiation. 
Although patients with asplenia are at increased risk 
of infections, recommendations regarding antibiotic 
prophylaxis are inconsistent. Patients with combined 
risk of asplenia and immunosuppression for GVHD 
should receive antibiotic prophylaxis as recommended 
below. Otherwise patients with asplenia should, at a 
minimum, be warned regarding the need for prompt 
medical attention for febrile illnesses. 
Aspergillus infection of the lungs or sinuses is 
the most commonly described late fungal infection 
although Candida and Mucor species are late patho-
gens seen infrequently. Late-onset cytomegalovirus 
(CMV) reactivation and infection has been reported 
more frequently in recent years with the increasing 
use of prophylactic or preemptive antiviral drugs in 
the early post-HCT period. Late CMV infections 
are most commonly seen in patients treated for early 
CMV infection or in those with chronic GVHD or 
late immune manipulation (eg, donor lymphocyte in-
fusion recipients). Varicella zoster virus (VZV) infec-
tion frequently occurs in the first year after transplan-
tation, especially in patients with chronic GVHD. 
In patients receiving prophylaxis against herpes vi-
rus infections, VZV reactivation is most commonly 
seen in the 2-3 months after cessation of prophylaxis. 
Acyclovir prophylaxis is recommended for 1-year 
posttransplantation for both autologous and allogene-
ic recipients at risk for VZV disease; prophylaxis may 
be continued beyond 1-year among patients who have 
chronic GVHD or require systemic immune-suppres-
sion. Recurrent herpes simplex virus infections can 
occasionally occur in patients with chronic GVHD.
Although Pneumocystis jirovecii (previously 
Pneumocystis carinii) pneumonia (PCP) generally oc-
curs during the first 6 months after HCT, patients are 
at risk for as long as immunosuppressive therapy is 
given for chronic GVHD. Autologous HCT recipi-
ents are also at risk of PCP, particularly during the 
first 6 months; the risk may be substantial if there has 
been prolonged corticosteroid exposure before or after 
transplantation and in patients who have received in-
tensive conditioning. 
Sinusitis is an occasional complication, especially 
after allogeneic HCT, and is more frequent in patients 
with low immunoglobulin levels. Sinus pathogens are 
rarely identified because invasive diagnostic proce-
dures are not frequently performed. Exposure to cal-
cineurin inhibitors that can induce mucosal hypertro-
phy and mucosal involvement by chronic GVHD can 
increase the risk of secondary sinus infections with 
bacteria or molds.
Supplemental intravenous immune globulin (IVIg) 
is sometimes recommended for patients with severe 
infections and IgG levels below 400 mg/dL (4 g/L) 
and infusions are continued until infection has abat-
ed.9,10 The use of prophylactic IVIg in HCT patients 
in the absence of infection remains controversial. 
Transplant recipients who reside in certain geo-
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graphic areas may be susceptible to locally prevalent 
infections (eg,, tuberculosis, malaria, Chagas disease, 
leishmaniasis). Health care providers taking care of 
such patients should be aware of guidelines for the pre-
vention and management of such infections.10,13,14 
Recommendations
1.  Patients with chronic GVHD should receive anti-
biotic prophylaxis targeting encapsulated organisms 
given for at least as long as immunosuppressive ther-
apy is administered. 
2.  Antiviral and antifungal prophylaxis should be con-
sidered in patients at high risk for viral and fungal in-
fections (eg,, patients with chronic GVHD) accord-
ing to published guidelines.9,10 Screening for CMV 
reactivation should be based on risk factors, includ-
ing intensity of immunosuppression. 
3.  Administration of prophylactic antibiotics for oral 
procedures should follow the American Heart 
Association guidelines for endocarditis prophylax-
is.15 Some experts recommend antibiotic prophylaxis 
before dental care in patients on immunosuppressive 
therapy for chronic GVHD and in patients with in-
dwelling central venous catheters.
4.  Allogeneic HCT recipients should receive PCP pro-
phylaxis from engraftment until at least 6 months 
after transplantation or as long as immunosuppres-
sive therapy is given (eg,, for the treatment or preven-
tion of chronic GVHD). PCP prophylaxis for 3 to 
6 months posttransplantation should be considered 
for autologous HCT recipients with substantial im-
munosuppression (eg, patients with lymphoma, leu-
kemia or myeloma, especially when pre-transplant 
treatments or conditioning regimens have included 
purine analogues or high dose corticosteroids). 
5.  Immunization with inactivated vaccines for all pa-
tients according to published guidelines (Appendix 
Table A).9-11 Since patients with chronic GVHD 
can mount responses to vaccines and are at risk for 
infections, postponing vaccination in patients with 
GVHD is not recommended with the exception of 
live vaccines. When vaccinating patients with active 
GVHD, it may be prudent to measure specific anti-
body levels before and after vaccination, to determine 
their level of protection and need for booster immu-
nizations. 
OCULAR COMPLICATIONS
There are three main ocular late effects after HCT. 
Anterior segment ocular complications of keratocon-
junctivitis sicca syndrome and cataracts are well de-
scribed. Ischemic microvascular retinopathy is a poste-
rior segment complication that is being increasingly rec-
ognized and appears to be related to radiation exposure.
Ocular sicca syndrome is usually part of a more gen-
eral sicca syndrome with xerostomia, vaginitis, and dry-
ness of skin and is associated with chronic GVHD.16 
Ocular manifestations include reduced tear flow, kera-
toconjunctivitis sicca, sterile conjunctivitis, corneal 
epithelial defects, and corneal ulceration. Symptoms 
include burning, irritation, pain, foreign body sensa-
tion, blurred vision, photophobia, and paradoxically, 
excessive tearing. The diagnosis of keratoconjunctivitis 
sicca is made by the presence of appropriate symptoms, 
evidence of decreased tear production on Schirmer’s 
test, and clinical signs of keratitis. In all cases, infec-
tious keratitis must be ruled out. The incidence is ap-
proximately 40-60% in patients with chronic GVHD.17 
Artificial tears can provide symptomatic treatment 
of dry eye. Information regarding frequency of use 
of artificial tear drops can indicate severity of dry eye 
syndrome. Treatment includes systemic treatment of 
chronic GVHD and topical treatment to increase lu-
brication, control evaporation or drainage, and decrease 
ocular surface inflammation.18 Temporary or perma-
nent occlusion of the tear-duct puncta for drainage 
control may provide benefit. In general, contact lens us-
age is discouraged in patients with keratoconjunctivitis 
sicca because of an increased risk of abrasion: however, 
some lenses such as scleral lenses may be beneficial in 
severe cases to control evaporation. Such an approach 
should occur only with the close supervision of an 
ophthalmologist. Topical corticosteroids or calcineurin 
inhibitors may improve symptoms but can cause sight-
threatening complications when inappropriately used 
in herpes simplex virus or bacterial keratitis. Ocular 
surface inflammation may be decreased with autolo-
gous serum, but this treatment is available in a limited 
number of centers.
Cataract formation occurs frequently after TBI ex-
posure. After myeloablative single-dose TBI, almost 
all patients develop cataracts within three to four 
years. Fractionation of TBI delays onset and reduces 
the incidence of cataract to 40-70% at ten years post-
transplant.19,20 In patients conditioned without TBI, 
the probability of cataract formation at 10 years is 
5-20%.20,21 Other risk factors for cataract formation 
after HCT are older age, use of corticosteroids, and 
allogeneic compared to autologous transplantation. 
Approximately 45% of recipients treated with cortico-
steroids for a prolonged period of time develop cata-
racts at 10 years. In the near future, the overall cumula-
tive incidence of cataracts after HCT is expected to de-
crease as fewer patients receive TBI based conditioning. 
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Cataracts are effectively treated surgically. Cataract ex-
traction can be performed safely even when ocular sicca 
is present. Surgery is indicated if vision is impaired and 
the impairment is interfering with daily life.
Ischemic microvascular retinopathy presents with 
cotton-wool spots and optic-disc edema. Retinopathy 
is observed almost exclusively after allogeneic trans-
plantation, particularly in patients conditioned with 
TBI and in patients receiving cyclosporine for GVHD 
prophylaxis. In most cases, retinal lesions resolve with 
withdrawal or reduction of immunosuppressive thera-
py, even in cases where visual acuity is decreased. Other 
ocular complications in the posterior segment include 
hemorrhage, optic disc edema, and infectious retinitis 
(eg,, from herpes viruses including CMV, toxoplasma, 
and fungi).
Recommendations
1.  Routine clinical evaluation of visual history and 
symptoms, with attention to sicca syndrome, is rec-
ommended at 6 months, 1 year and yearly thereafter 
for all HCT recipients. 
2.  Referral to an expert in ophthalmology for routine 
ocular examination with measurement of visual acu-
ity and fundus examination at 1 year after transplant 
is recommended for all HCT recipients. Patients 
with chronic GVHD may be referred for ophthal-
mologic exam sooner than 1 year posttransplant. 
Subsequent frequency of routine screening should be 
individualized according to recognized defects, ocu-
lar symptoms or the presence of chronic GVHD. 
3.  Patients experiencing visual symptoms should un-
dergo ocular examination immediately.
ORAL COMPLICATIONS
Late complications involving the oral cavity are com-
mon after HCT. The most important risk factors for 
oral late effects are oral chronic GVHD, the use and 
dose of irradiation to head and neck region, underlying 
diagnosis of Fanconi anemia and the age of the patient 
at HCT. Pre-transplant evaluation should include clini-
cal assessment of oral health status to serve as a baseline 
for monitoring posttransplant oral complications. 
 The mouth is one of the most frequently affected 
organs in chronic GVHD.22,23 The oral changes involv-
ing the oral mucosa, salivary glands, oral and lingual 
muscles, taste buds and gingiva may completely regress, 
but some long term sequela may continue despite the 
resolution of chronic GVHD. Patients often report oral 
pain, dryness, odynophagia, dysphagia and sensitivity 
(irritation from normally tolerated spices, foods, liquids 
or flavors) that may limit oral intake. The presence of 
lichen planus, hyperkeratotic plaques and restriction of 
mouth opening by peri-oral fasciitis or skin sclerosis are 
diagnostic signs of oral GVHD. Patients may also have 
mucosal erythema, atrophy, oral dryness, mucoceles 
(due to inflammation and obstruction of the salivary 
gland ducts), pseudomembranes and ulcers. Salivary 
gland dysfunction and xerostomia increase the risk of 
dental caries, periodontal disease and oral cancer.22,24 
Patients with GVHD can be treated with topical oral 
steroids, systemic treatments for GVHD, and support-
ive care for xerostomia symptoms as outlined below.
Even in patients who have never had GVHD, some 
degree of salivary gland hypofunction may persist for 
prolonged periods of time after receiving chemothera-
py, and especially after local irradiation. Oral dryness 
is also a side effect of commonly used medications (eg, 
antidepressants, anti-histamines, diuretics, muscle re-
laxants and some analgesics). Medication lists should 
be reviewed to identify and eliminate any drugs that 
can cause or exacerbate xerostomia. Depending on the 
severity of xerostomia, patients may complain of oral 
sensitivity, abnormal taste and may feel a constant sore 
throat, or have problems speaking and swallowing. The 
decrease in salivation predisposes patients to dental de-
cay, oral infections (eg, herpes simplex and oral candi-
diasis), mechanical and epithelial injuries, and impairs 
re-mineralization of teeth. Xerostomia can be difficult 
to manage. Symptom relief can be achieved with artifi-
cial saliva and oral rinses; sugar-free candies or gum can 
stimulate the saliva flow. Sialogogues (eg, pilocarpine, 
cevimeline) may be tried in adults. Frequent sipping of 
water may help decrease symptoms, and especially help 
chewing and swallowing food. Patients with xerosto-
mia should receive meticulous oral hygiene, undertake 
preventive measures for dental and periodontal disease, 
and aggressive treatment of oral infections. Further 
trauma to the oral mucosa should be avoided and 
mouth-guards may be used, if necessary. Oral piercing 
should be avoided. 
Squamous cell oral cancer can arise from the buc-
cal mucosa, salivary glands, gingiva, lip or tongue (see 
section on Secondary Cancers).24-26 Patients with a his-
tory of oral chronic GVHD and patients with Fanconi 
anemia are particularly at risk and must be carefully 
screened throughout their lives. Frequent self and pro-
fessional oral examination is the mainstay for early di-
agnosis of oral cancer. Patients should be vigilant for 
and report lesions that do not heal, leukoplakia, local-
ized pain and changes in color or texture of the muco-
sa. Patients with Fanconi anemia should be examined 
every six months and oral examination should be part 
of the standard annual examination of all other HCT 
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patients.
Children undergoing HCT may have damage to 
the enamel layer and the teeth may have discolored 
patches or stain easily. Depending on the child’s age, 
permanent teeth may start developing again within 
a few months of transplantation. Normal dental de-
velopment may be altered in 50%-80% of children 
due to prior therapies or conditioning regimen expo-
sure.27 Tooth agenesis, hypodontia, microdontia of the 
crowns of erupted permanent teeth, narrowing of the 
pulp canal, thinning and tapering of the roots of erupt-
ed permanent molars or incisors, delayed eruption and 
primary tooth retention have been described and may 
jeopardize occlusal development. After irradiation, 
underdevelopment of the mandible and anomalies 
in the mandibular joint may also occur. Young age at 
HCT and exposure to TBI are important risk factors 
for problems with dental development. 
 Among HCT recipients who require dental proce-
dures, the American Heart Association recommenda-
tions for antimicrobial prophylaxis against endocardi-
tis should be followed (see section on Immunity and 
Infections).15 
Recommendations
1.  All HCT recipients should be educated about pre-
ventive oral health and routine dental maintenance. 
Patients should also be counseled to avoid smok-
ing and chewing tobacco, decrease regular intake 
of sugar containing beverages, and avoid intraoral 
piercing.
2.  Clinical oral evaluations should be performed at 6 
months, 1 year and yearly thereafter. More frequent 
evaluations may be needed in patients at high-risk 
of oral complications (eg, chronic GVHD, exposure 
to TBI). Monitoring of oral complications post-
transplantation is facilitated by thorough pre-HCT 
baseline oral assessment
3.  Patients at high-risk for squamous cell cancers of 
the oral cavity (eg,, oral chronic GVHD, Fanconi 
anemia) should undergo clinical oral evaluations 
every six months and should be educated to main-
tain meticulous oral hygiene and taught oral self-
inspection.
4.  All HCT recipients should receive a thorough 
evaluation by a dentist or oral medicine specialist 
at 1 year after HCT and yearly thereafter. More 
frequent dental consultations may be considered in 
patients with oral GVHD or Fanconi anemia. At 
each visit it is important to check for a history of xe-
rostomia and high-risk habits, to perform a through 
oral, head and neck and dental exam. Appropriate 
dental and radiologic assessment for tooth develop-
ment should be performed in children. 
RESPIRATORY COMPLICATIONS
Late pulmonary complications among HCT recipients 
include idiopathic pneumonia syndrome, bronchiolitis 
obliterans syndrome (BOS), cryptogenic organizing 
pneumonia (COP) and sino-pulmonary infections.28 
Allogeneic HCT recipients have higher risks than au-
tologous HCT recipients. Predisposing factors can in-
clude infections, extent and type of pre-transplant and 
conditioning regimen chemotherapy and radiation ex-
posure, and GVHD. Pulmonary complications can be 
associated with significant morbidity and mortality. 
 Idiopathic pneumonia syndrome, also known as in-
terstitial pneumonitis, more commonly presents in the 
early posttransplant period. However, it can occur in 
long-term survivors and can lead to late respiratory im-
pairment. Predisposing factors include allogeneic HCT, 
exposure to high dose TBI, and GVHD. Immune com-
promise delays recovery from infection, allowing greater 
damage to the lung interstitium. Certain chemothera-
peutic agents (eg,, BCNU, bleomycin, busulfan, metho-
trexate) can cause lung toxicity directly or can enhance 
the damaging effects of radiation. Fractionation of ra-
diation and lung shielding can decrease radiation toxic-
ity. Prophylaxis strategies focus on decreasing the risks 
of infections post-HCT, especially among patients with 
chronic GVHD. 
 BOS occurs in 2-14% of allogeneic HCT recipi-
ents and is almost exclusively seen among patients with 
chronic GVHD; some experts classify BOS as pulmo-
nary GVHD.29-31 BOS may develop in patients with 
no other clinical manifestations of GVHD. BOS is 
characterized by the new onset of an obstructive lung 
defect and clinically manifests as dyspnea on exertion, 
cough or wheezing. Patients may be asymptomatic early 
in the disease process. BOS is clinically diagnosed when 
all of the following criteria are met together with ac-
tive chronic GVHD in at least one organ other than 
the lung: (1) forced expiratory volume in 1 second 
(FEV1)/forced vital capacity ratio <0.7 and FEV1 
<75% of predicted, (2) evidence of air trapping or small 
airway thickening or bronchiectasis on high resolution 
chest computed tomography, residual volume >120%, 
or pathologic confirmation of constrictive bronchiolitis, 
and (3) absence of infection in the respiratory tract, 
documented with investigations (eg, bronchoalveolar 
lavage) directed by clinical symptoms. Some experts 
consider a decrease in the FEV1 of 10% or greater 
from pre-transplant baseline as a diagnostic criterion 
for BOS or an indication for more frequent follow-up 
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pulmonary function test (PFT) assessments. The value 
of using spirometry to screen for BOS in the absence 
of symptoms is not well defined. Treatment of BOS 
includes immunosuppressive agents such as corticoste-
roids, calcineurin inhibitors, sirolimus and anti-thymo-
cyte globulin. The prognosis of BOS is poor, and 5-year 
survival rates are <20% if patients do not respond to 
initial treatment.30,31
COP, previously known as bronchiolitis obliterans 
organizing pneumonia, is a clinicopathologic syndrome 
that involves the bronchioles, alveolar ducts and the al-
veoli and is the result of a variety of toxic, immunologi-
cal or inflammatory injuries to the lungs. COP presents 
typically in the first 6 to 12 months posttransplantation, 
although later onset may occur, especially in patients 
with chronic GVHD. Clinical presentation includes 
non-productive cough, low grade fevers and dyspnea. 
Radiologic imaging may reveal patchy consolidation 
with ground glass or nodular infiltrates. Pulmonary 
function tests typically show a restrictive pattern. 
Biopsy may be needed to confirm the diagnosis of COP. 
Mainstay of treatment is corticosteroids and 80% of pa-
tients can be expected to recover, but relapses are com-
mon if steroids are rapidly tapered. This complication is 
rare after transplantation and no specific screening tests 
are available for early diagnosis and prevention. 
Recurrent sino-pulmonary infections can oc-
cur in patients with delayed immune reconstitution 
and chronic GVHD (see section on Immunity and 
Infections). Appropriate vaccination is recommended, 
and in patients with ongoing immune deficiency and in-
fections, monitoring of immune globulin levels should 
be considered with targeted replacement as recom-
mended elsewhere in these guidelines. 
 Other rare late complications involving the lung in-
clude diffuse alveolar hemorrhage, pulmonary throm-
bo-embolism, pulmonary veno-occlusive disease and 
pleural effusions. 
Recommendations
1.  Routine clinical assessment by history and physical 
exam for pulmonary complications is recommended 
for all patients at 6 months, 1 year and yearly there-
after. 
2.  Some experts recommend earlier and more frequent 
clinical assessments including PFT’s in patients with 
chronic GVHD. 
3.  History of smoking should be assessed and patients 
who smoke or are at risk for passive smoking should 
be counseled regarding smoking cessation. 
4.  In patients with symptoms or signs of lung com-
promise, PFT’s and focused radiologic assessment 
should be performed as clinically indicated. Follow-
up evaluations should be guided by clinical circum-
stances for patients with recognized defects.
CARDIAC AND VASCULAR COMPLICATIONS
In comparison to other complications, clinically evident 
cardiac and cardiovascular complications after HCT 
are rare. Cardiac toxicity accounts for late deaths in 
2% autologous and 3% of allogeneic HCT recipients. 
However, it is likely that cardiac and vascular compli-
cations are still underestimated. Experiences of cancer 
survivorship in the non-transplant setting may provide 
an estimate of the magnitude of risk in HCT recipients. 
In a cohort of 1474 long-term survivors with Hodgkin 
lymphoma (among whom 84% received mediastinal ra-
diation), the risk of cardiac and cardiovascular diseases 
was 3 to 5 times increased compared to a general popu-
lation.32 Therefore, cardiac and cardiovascular compli-
cations may increase with longer follow-up after HCT.
Late cardiac events can appear years and even de-
cades after HCT, and may manifest as subclinical ab-
normalities or present as overt congestive heart failure 
or angina. The cardiac complications include any cardi-
ac dysfunction due to cardiomyopathy, valvular anom-
aly, or conduction anomaly. Many factors are involved, 
such as the cumulative exposure to anthracyclines and 
chest radiation prior to HCT, cardiac function before 
transplantation, intensity and type of conditioning regi-
men used, as well as posttransplant factors. Previous 
use of cardiotoxic chemotherapy and chest radiation 
plays a major role. For patients with non-malignant 
diseases such as hemoglobinopathy or aplastic ane-
mia, transfusion history and the resultant iron over-
load may be important. With advancing age at time of 
HCT, common pre-existing cardiac diseases may be 
increased. Assessment prior to transplantation for all 
HCT recipients should include inquiry about exposure 
to pre-transplant chemotherapy (eg,, cumulative dose 
of anthracyclines) and chest and neck radiation therapy, 
and evaluation of pre-existing cardiac and cardiovascu-
lar disease.
Anthracycline cardiomyopathy is characterized by 
a dose-dependent progressive decrease in systolic left 
ventricular function. At total doses of less than 400 
mg/m2 body surface area, the incidence of congestive 
heart failure is 0.14%; this incidence increases to 7% at 
a dose of 550 mg/m2 and to 18% at a dose of 700 mg/
m2. Mediastinal radiotherapy applied before HCT can 
cause a variety of cardiac complications by producing 
inflammation and fibrosis of all structures of the heart. 
Restrictive cardiomyopathy, fibrosis of the electrical 
conduction pathways with arrhythmias, and autonomic 
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dysfunction, as well valvular defects, with left-sided 
valve regurgitation and valve thickening are the delete-
rious consequences. 
Cardiovascular disease involves changes of the whole 
arterial vascular network and can include cerebrovascu-
lar disease, ischemic heart disease and peripheral arte-
rial disease after HCT. These cardiovascular events 
may have diverse clinical manifestations, such as stroke, 
transient ischemic attack, myocardial infarction, angina 
pectoris, chronic coronary artery disease, ischemic leg 
pain or gangrene. 
 In a retrospective single center study, the cumula-
tive incidence of a cardiovascular complication was 22% 
at 25 years after allogeneic HCT.33 The relative risk of 
developing a late arterial event was significantly higher 
after allogeneic than after autologous HCT, supporting 
the hypothesis that the allo-reaction may be involved in 
the atherosclerotic process. The established cardiovas-
cular risk factors (hypertension, dyslipidemia, diabetes, 
smoking, physical inactivity) were associated with high-
er risks of cardiovascular complications posttransplan-
tation. Some conditioning regimens may have inherent 
cardiac toxicity with long-term cardiac consequences.34 
 A high prevalence of metabolic syndrome, elevated 
triglycerides, elevated blood pressure, abdominal obe-
sity and diabetes has been reported among allogeneic 
HCT survivors, even when off immunosuppressive 
treatment. Prolonged and intensified immunosuppres-
sive treatment, posttransplant endocrine dysfunction 
and insulin and/or leptin resistance could be some of 
the possible causes. Although studies supporting evi-
dence based guidelines are lacking in HCT, prevention 
and early treatment of the cardiovascular risk factors 
may decrease the risk of late cardiovascular complica-
tions after HCT.35 
Recommendations
1.  Routine clinical assessment and cardiovascular risk 
factor evaluation for all HCT recipients at 1 year and 
yearly thereafter. More frequent assessments and if 
clinically appropriate, extended cardiac evaluations 
(eg,, electrocardiogram, echocardiogram) may be 
indicated in patients at high-risk for cardiac compli-
cations (eg,, patients with Hodgkin lymphoma who 
have received mediastinal radiation therapy, patients 
with amyloidosis, and patients with pre-existing car-
diac and vascular abnormalities).
2.  Education and counseling on “heart” healthy life style 
(regular exercise, maintaining healthy weight, no 
smoking, dietary counseling) for all HCT recipients 
(see section on General Screening and Preventive 
Health). 
3.  Appropriate treatment of cardiovascular risk fac-
tors such as diabetes, hypertension and dyslipidemia 
for all HCT recipients. Among patients started on 
drug therapy for dyslipidemia, follow-up assessments 
should be performed based on published guidelines 
(fasting lipid panel every 6-8 weeks till treatment goal 
is achieved and then every 4-6 months).36
4.  Endocarditis prophylaxis in HCT recipients accord-
ing to the recommendations of the American Heart 
Association (Appendix Table C).15
LIVER COMPLICATIONS
Late liver complications are most commonly related to 
medications, chronic GVHD, hepatitis B or C virus 
(HCV), or iron overload.37 The etiology of liver dys-
function may be multifactorial, and a careful history, 
physical examination, and review of medications can 
often provide clues. In addition, the time course of on-
set and pattern of liver function test abnormalities, his-
tory of pre-transplant hepatitis, diagnosis of GVHD at 
other sites, and number of blood transfusions pre- and 
post- transplantation can be useful in determining the 
etiology of liver disease. 
Chronic GVHD is a major cause of liver dysfunc-
tion after transplantation and can manifest with el-
evations of serum alanine transaminase, alkaline phos-
phatase, and gamma glutamyl transferase. Evaluation 
should exclude other causes of liver dysfunction (eg,, 
viral infections, drug injury). Liver biopsy should be 
performed to confirm the diagnosis when liver dys-
function occurs as the only manifestation of chronic 
GVHD and systemic immunosuppression is being 
considered. Immunosuppressive therapy is indicated 
for liver chronic GVHD; ursodeoxycholic acid may be 
used as an adjunct. Liver transplantation has success-
fully been performed in several rare cases of progressive 
liver failure.38 
Long-term survivors with hepatitis B generally have 
mild to moderate liver disease. Chronic HCV infection 
is often asymptomatic with fluctuating transaminase 
levels as the only manifestation during the first de-
cade following transplantation. However, the cumula-
tive incidence of HCV progressing to cirrhosis is 11% 
at 15 years and 24% at 20 years, being more rapid in 
transplant than non-transplant patients (18 versus 40 
years).39 Extrahepatic HCV disease and genotype 3 
are associated with progression to cirrhosis. In patients 
with known HCV infection, liver biopsy can be consid-
ered at 8 to 10 years after transplantation to assess for 
the presence of cirrhosis. 
HCT recipients are at risk of developing iron 
overload primarily from red blood cell (RBC) trans-
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fusions as part of their supportive care both pre- and 
post- transplantation, although increased iron absorp-
tion due to ineffective erythropoiesis and a carrier state 
for hereditary hemochromatosis, if present, may also 
contribute.40 Iron overload in late survivors has been 
associated with increased infections and may mimic 
hepatic chronic GVHD. Although serum ferritin is a 
sensitive test for iron load, as an acute phase reactant, it 
is not a specific test. When iron overload is suspected, 
the hepatic iron content should be estimated by appro-
priate imaging (specialized magnetic resonance imag-
ing [MRI] protocols or superconducting quantum in-
terference device [SQUID]) or liver biopsy. MRI and 
SQUID are noninvasive tests and have been shown to 
be sensitive and specific for quantifying liver iron con-
tent. These are the preferred methods unless a tissue 
sample is needed to assess for other potential etiologies 
of liver dysfunction. Survivors with mild iron overload 
may not require any therapy, as there are reports of iron 
load decreasing with time, but should be counseled to 
avoid iron supplements and alcohol ingestion. Although 
more data is needed to determine the incidence of end 
organ damage from iron overload, patients with signifi-
cant iron overload (eg,, >7 mg/gm dry weight liver iron) 
and liver dysfunction are candidates for phlebotomy or 
iron-chelation therapy. Iron-chelation therapy prior to 
or early posttransplant is being investigated in patients 
with pre-transplant iron overload. Among patients who 
are at risk for iron overload and require vitamin supple-
mentation, iron-free preparations should be considered. 
HCT recipients who have thalassemia or have been 
heavily transfused pre-transplantation (eg, other hemo-
globinopathies and bone marrow failure syndromes) 
are particularly at risk for iron overload and acquired 
HBV and HCV infections. 
Recommendations
1.  Liver function tests (total bilirubin, alkaline phos-
phatase, and transaminases) should be performed 
every 3-6 months for the first year and then at least 
yearly thereafter. More frequent assessments may be 
needed based on an individual patient’s medical sta-
tus (eg,, patients with GVHD), and particularly in 
allogeneic transplant survivors.
2.  Patients with hepatitis B and C should have viral load 
monitored by polymerase chain reaction (PCR) and 
consultation with liver and infectious disease spe-
cialists for antiviral therapy is advised. Liver special-
ists may recommend a liver biopsy in patients with 
chronic HCV infection to determine the extent of 
cirrhosis. This is particularly important in patients 
8-10 years post transplant.
3.  Serum ferritin should be measured at 1 year post 
transplant in patients who received RBC infusions 
pre- or posttransplant. Subsequent monitoring with 
serum ferritin should be considered among patients 
with elevated levels, especially in the presence of ab-
normal liver function tests, continued RBC transfu-
sions, or HCV infection. Additional diagnostic test-
ing (eg,, liver biopsy, MRI or SQUID) may be indi-
cated if therapy is contemplated for suspected iron 
overload. 
RENAL AND GENITOURINARY 
COMPLICATIONS 
Renal dysfunction among HCT survivors can be 
caused by a number of exposures in the pre-, peri- and 
posttransplant period. The incidence of chronic kidney 
disease (CKD), defined as sustained decrease in glo-
merular filtration rate below 60 ml/min/1.73 m2, has 
been reported to range from 5-65%.41,42 CKD usually 
becomes apparent 6 to 12 months after transplant, al-
though it can occur earlier as well as much later post-
transplantation. Renal dysfunction may present as 
thrombotic micro-angiopathy, glomerulonephritis or 
nephrotic syndrome and radiation nephritis may occur 
after exposure to TBI. The majority of patients have an 
idiopathic form of CKD, which is not associated with 
thrombotic micro-angiopathy or nephrotic syndrome 
and has a multifactorial etiology. 
 Risk factors for CKD in long-term survivors of 
HCT include older age at HCT, diagnosis (eg, my-
eloma) and pre-transplant renal function and therapy 
exposures (eg, platinum compounds), acute and chronic 
GVHD, use of TBI in conditioning regimen, and ex-
posure to medications to prevent or treat GVHD (eg, 
calcineurin inhibitors) and certain antimicrobials (eg, 
acyclovir, amphotericin B, aminoglycoside antibiot-
ics).42,43 Antibiotics and antifungal agents cause tubular 
rather than glomerular damage. Calcineurin inhibitors 
can cause glomerular thrombosis and tubular injury. A 
long term syndrome of calcineurin inhibitor associated 
renal injury can affect both renal arterioles and tubules 
and can be accompanied by interstitial fibrosis. CMV 
infection has also been associated with glomerular inju-
ry and the use of foscarnet for CMV infection can fur-
ther induce tubulointerstitial nephritis and irreversible 
damage due to crystallization within the renal tubules. 
Radiation exposure (eg, TBI) can lead to degeneration 
and sclerosis of arterioles and secondary destruction of 
glomeruli and tubules.
Patients with substantial hemorrhagic cystitis in the 
early posttransplant period experience a greater risk of 
later bladder wall scarring and contraction. Evaluation 
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and treatment of polyoma or adeno viruses may be 
warranted in some patients with hemorrhagic cystitis, 
especially if they have received extended duration of 
immunosuppressive therapy. Patients receiving immu-
nosuppressive therapy for chronic GVHD, particularly 
women with GVHD of the vulva and vagina are at risk 
of recurrent urinary tract infections.
Recommendations regarding complications of the 
genital and reproductive organs are also addressed in 
the Endocrine Complications and Mucocutaneous 
Complications sections. 
Recommendations
1.  Blood pressure should be checked at every clinic visit, 
and hypertension should be investigated and man-
aged appropriately in all HCT recipients (see section 
on General Screening and Preventive Health). 
2.  Renal function should be evaluated at 6 months, 1 
year and at least yearly thereafter for all HCT recipi-
ents. Screening should include assessment of BUN, 
creatinine and urine protein. Further workup (eg, re-
nal ultrasound, renal biopsy), as clinically indicated 
should be pursued in patients with late onset acute 
renal failure or CKD posttransplantation. More fre-
quent assessments may be needed based on an indi-
vidual patient’s medical status (eg,, ongoing therapy 
with calcineurin inhibitors). 
3.  In patients with progressive CKD, avoid nephrotox-
ins and consider early referral to a nephrologist for 
evaluation and treatment. 
COMPLICATIONS OF MUSCLE AND 
CONNECTIVE TISSUE
Major late complications affecting muscle and connec-
tive tissue after HCT include steroid-induced myopa-
thy, fasciitis/scleroderma and polymyositis. One case-
matched control study reported that 35% of 10-year 
survivors after HSCT still complain of musculoskeletal 
stiffness, cramps, weakness and joint swelling, and the 
incidence of musculoskeletal problems was significantly 
higher than controls.44 Possible causes of these prob-
lems may include sedentary lifestyle combined with 
muscle loss, myopathy or fibromyalgia related to steroid 
treatment, or scleroderma/fasciitis related to chronic 
GVHD. 
Myopathy after HCT is one of the most frequent 
complications of long-term steroid therapy for chronic 
GVHD. It is associated with moderate to severe func-
tional impairment and may be associated with an in-
creased risk of mortality. Proximal lower extremity 
muscles are commonly involved with the quadriceps 
muscle being most severely affected. The myopathy pro-
gresses insidiously in most cases. Clinical observation of 
a patient changing position from a supine to sitting or 
sitting to standing may reveal early myopathy. The use 
of a questionnaire such as the Human Activity Profile 
(HAP) may lead to its early detection.45 Posttransplant 
fatigue contributes to inactivity which exacerbates mus-
cle atrophy. Therefore, it is also important to encourage 
progressively increasing physical activity to stop this vi-
cious cycle.
Myositis or polymyositis is a distinctive feature of 
chronic GVHD as defined by NIH consensus crite-
ria.29 Although the incidence of myositis in patients 
with chronic GVHD is much higher than in the gen-
eral population, it is a rare complication after HCT. 
Chronic GVHD associated polymyositis or myopathy 
usually occurs 2-5 years after HCT and the common 
presenting symptoms are moderate to severe proximal 
muscle weakness and/or myalgia. Lower extremities 
are more commonly involved. This syndrome may be 
hard to distinguish from steroid induced myopathy. 
The majority of patients have elevated serum creatinine 
kinase (CK), a myopathic pattern on electromyography 
(EMG), a largely peri-fascicular lymphocytic infiltra-
tion on muscle biopsy and very favorable response to 
immunosuppressive therapy.46 It is often a challenge to 
differentiate the muscular weakness of chronic GVHD 
associated myositis or myopathy from that of steroid 
myopathy/peripheral neuropathy as a few patients 
with chronic GVHD associated myopathy have a nor-
mal CK and lack lymphocytic infiltration in the muscle 
biopsy. 
Sclerosis can affect the skin and subcutaneous tis-
sues including fasciae, joints and the musculoskeletal 
system with varying degrees of severity and is a diag-
nostic feature of chronic GVHD. Early involvement 
of fasciae and tendons is associated with edema and an 
eosinophilic infiltrate, with later progression to fibro-
sis and joint contractures, most commonly in fingers, 
wrists, shoulders, elbows and ankles. Inflammation of 
the synovium may produce joint effusion. As sclerosis 
progresses insidiously, early detection is often difficult. 
Aggressive and prolonged immunosuppressive therapy 
is necessary to prevent progression of contractures, 
but it is usually ineffective at reversing established 
contractures. Early intervention and rehabilitation be-
come essential to restore range of motion and strength. 
Stretching exercises and myofascial massage are impor-
tant to help improve the range of motion of affected 
joints and to restore functions of daily living.18 Regular 
survey of range of motion at all target joints by clini-
cians as well as patients is also essential to detect early 
and potentially reversible limitation of movement.
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 The presence of a variety of auto-antibodies such 
as anti-smooth muscle, anti-nuclear and anti-mito-
chondrial antibodies after HCT has been observed, but 
in most cases they are not associated with any clinical 
symptoms. However, in rare cases donor-derived anti-
acetylcholine receptor antibodies may be present with 
clinical manifestations of myasthenia gravis.47 Adoptive 
transfer of abnormal lymphocyte clones has been sug-
gested as a possible mechanism, but immune dysregu-
lation associated with concomitant chronic GVHD 
might be a contributing factor.
Recommendations
1.  All HCT recipients should follow general population 
age-specific guidelines for physical activity (See sec-
tion on General Screening and Preventive Health). 
2.  For patients on corticosteroids, frequent clinical eval-
uation is recommended for steroid-induced myopa-
thy by manual muscle tests or by assessing patients’ 
ability to go from a sitting to a standing position. 
3.  Patients with muscle weakness, myalgias, or arthral-
gias should be evaluated for possible chronic GVHD 
or steroid associated myositis, and other muscular 
disorders (eg, myasthenia gravis). 
4.  Among patients with chronic GVHD, joint range of 
motion should be evaluated to detect sclerotic chang-
es. Patients should also be instructed to perform self-
assessment of range of motion.
5.  Where prolonged corticosteroid exposure is antici-
pated or when fasciitis or scleroderma develops, a 
physical therapy consultation should be considered 
to establish baseline function and provide range of 
motion and muscle strengthening exercises to mini-
mize loss of function.
SKELETAL COMPLICATIONS
Bone density loss is a well recognized complication of 
HCT. There is a wide variation in the reported inci-
dence of this complication; some studies have reported 
incidence rates as high as 25% for osteoporosis and 
50% for osteopenia.48-51 Rapid loss of bone usually 
takes place within 6 to 12 months after transplantation. 
Certain patients are more susceptible to bone loss in-
cluding elderly, women, patients with low body weight 
(body mass index <20 to 25 kg/m2), patients who are 
physically inactive, and patients who receive extended 
corticosteroid therapy for their underlying disease be-
fore transplantation or for GVHD after transplanta-
tion. Some experts consider prolonged corticosteroid 
exposure as use of ≥5 mg prednisone equivalent daily 
for >3 months.52 Providers should also consider corti-
costeroid exposure pre-transplantation when determin-
ing risk for bone loss (eg,, as part of treatment regimens 
for lymphoma and acute lymphoblastic leukemia). The 
use of calcineurin inhibitors and other immunosup-
pressive therapy may increase the risk for this complica-
tion.
 Studies suggest that both the total cumulative dose 
and the duration of corticosteroid therapy are impor-
tant factors for the development of osteopenia.48 Other 
possible contributing factors include hypogonadism, 
secondary hyperparathyroidism due to the decrease in 
serum levels of calcium and vitamin D, and direct toxic-
ity from conditioning to bone cells and bone marrow 
stromal cells. Standard preventive measures include 
adequate physical activity in the posttransplant period, 
use of supplemental calcium and vitamin D, and con-
sideration of estrogen replacement therapy in deficient 
women. 
Dual photon densitometry is currently the best tool 
to assess the degree of bone loss. Osteopenia and osteo-
porosis are differentiated by the degree of reduction in 
bone mass and can be quantified by T and Z scores by 
dual photon densitometry. Normal values of bone den-
sity have not been well established in children, although 
it is clear that the loss of bone density and increased 
risk of fracture is a significant issue in children after 
HCT. The femur neck and lumbar spine are the two 
most frequently measured sites by bone densitometry. 
Studies have shown differential effects in the extent 
and length of post-HCT bone density loss. Bone loss is 
more severe, persistent and resistant to therapy in cor-
tical bones such as the femur neck than in trabecular 
bones such as the spine.
 Treatment choices for patients with established 
osteopenia and osteoporosis include active exercise, 
calcium and vitamin D supplementation, use of estro-
gen replacement in women, and minimizing the total 
exposure and duration of steroid and other immune-
suppressive therapy, if possible.48 Bisphosphonate ther-
apy should be considered for treatment of patients with 
established osteopenia and osteoporosis, patients with 
evidence of progressive bone density loss, and patients 
at high risk for bone loss (eg, patients with GVHD on 
extended steroid therapy). The optimal schedule and 
duration of bisphosphonate therapy in HCT is not 
well established. Bisphosphonate therapy has also been 
used in addition to calcium and vitamin D supplemen-
tation as a preventive measure for patients at high risk 
for osteopenia and osteoporosis, although the data for 
this intervention are less clear. Osteonecrosis of the jaw 
has been reported in patients receiving bisphosphonates 
for osteoporosis, especially among those undergoing 
oral procedures while on these agents.53 If appropriate, 
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dental evaluation should be performed before starting 
bisphosphonates in order to detect and correct any den-
tal problems. Long term use of bisphosphonates may be 
associated with subtrochanteric fractures of the femur; 
extended duration of therapy with these agents should 
be carefully considered until more information about 
this association becomes available.54
Avascular necrosis (AVN) has been described in 4%-
19% of HCT survivors. In addition to the risk factors 
for post-HCT bone loss, inflammatory microvascular 
changes related to GVHD or other factors may con-
tribute to this complication.55,56 TBI has been associated 
with a higher incidence of AVN in some reports. Joint 
pain or discomfort is usually the first manifestation of 
AVN and standard radiographic evaluation may not de-
tect abnormalities until late in the disease course. Joint 
symptoms in patients at risk should prompt MRI for 
early detection. While the hip is the most frequently af-
fected joint (over 80% of cases; bilateral in more than 
60%), other joints can be affected including the knees, 
wrists and ankles. Symptomatic relief of pain and ortho-
pedic measures to decrease pressure on the joint can be 
helpful. Most adult patients with advanced AVN will 
require surgical intervention. Orthopedic procedures 
including core decompression in early cases and joint 
replacement provide a satisfactory outcome in most pa-
tients. However, long term follow up of these procedures 
is needed in younger patients with a long life expectancy.
Recommendations
1.  A screening dual photon densitometry should be per-
formed at 1 year after transplantation in adult women, 
all allogeneic HCT recipients and patients who are 
at high risk for bone loss after transplantation (eg,, 
prolonged treatment with corticosteroids or calcineu-
rin inhibitors). Repeat densitometry should be per-
formed in those with recognized defects, ongoing risk 
factors or to follow up response to therapy. Physicians 
should evaluate gonadal and other related endocrine 
abnormalities in patients with decline in bone density.
2.  Patients should be counseled about preventive mea-
sures for bone loss and fractures such as physical exer-
cise, fall prevention, and vitamin D and calcium sup-
plementation. Hormone replacement therapy should 
be discussed with women who have estrogen deficien-
cy. Some experts recommend the use of bisphospho-
nates for patients at high risk for bone loss. 
3.  Screening for AVN is not recommended; however, 
clinicians should maintain a high level of suspicion 
for patients with exposure to irradiation or prolonged 
corticosteroids and evaluate patients with joint symp-
toms promptly. 
CENTRAL AND PERIPHERAL NERVOUS 
SYSTEM COMPLICATIONS
Neurological complications after HCT may affect the 
central and peripheral nervous system and are mostly 
secondary to infections, drug related toxicity and meta-
bolic encephalopathy. The effect on cognitive function 
and level of alertness can be subclinical with white mat-
ter changes detected up to a year later. The reported 
complication rate is higher in allogeneic, especially 
alternative donor HCT, as compared to autologous 
HCT recipients.57,58
Complications include central nervous system infec-
tions in immunocompromised recipients and vascular 
complications such as stroke and calcineurin inhibitor 
induced neurotoxicity. Leukoencephalopathy may oc-
cur as sequela of intrathecal chemotherapy and cranial 
irradiation. Patients who have received TBI or cranial ir-
radiation are at increased risk of secondary solid tumors 
of the brain on long term follow up. Children exposed 
to TBI are also at risk for developmental delays. There is 
growing evidence of a GVHD effect on the central ner-
vous system. A cerebral angiitis like syndrome has been 
described with cerebral ischemic lesions and leukoen-
cephalopathy secondary to GVHD. Guillain-Barre 
like syndrome with peripheral neuropathy and chronic 
demyelinating polyneuropathy related to GVHD has 
been reported.47,59,60 Peripheral neuropathy after HCT 
may be related to chemotherapy exposure.
 Neuropsychological deficits have been described 
in nearly 20% of recipients and cognitive deficits in ap-
proximately 10% of HCT recipients. Patients with a 
history of central nervous system disease (eg,, adenos-
ine deaminase deficiency associated severe combined 
immunodeficiency) and children treated with cranial 
radiation alone or in combination with chemotherapy 
are at higher risk. Cognitive changes may be subtle and 
difficult to detect making it imperative for the clinician 
to be vigilant even in patients who do not have any spe-
cific complaints.59,61 Neurocognitive function generally 
improves over time, but long-term deficits can remain 
in more than 40% of survivors.62
Recommendations
1.  All HCT recipients should undergo clinical assess-
ment for symptoms or signs of neurologic dysfunc-
tion at 1 year after HCT and at least yearly there-
after. Earlier and more frequent evaluations may be 
considered in high-risk patients (eg,, allogeneic HCT 
recipients, patients receiving prolonged immune sup-
pression with calcineurin inhibitors, patients receiv-
ing TBI, cranial radiation or intrathecal chemothera-
py and patients with chronic GVHD). 
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2.  Evaluation for cognitive developmental milestones 
should be performed at least annually in pediatric pa-
tients. Adult patients should be queried annually for 
changes in cognitive function, which may be subtle. 
3.  Further evaluation (eg,, MRI, nerve conduction stud-
ies, electromyography, neuropsychiatry testing) may 
be warranted in recipients with symptoms or signs of 
neurologic or cognitive dysfunction.
ENDOCRINE COMPLICATIONS
Chemotherapy, radiation therapy and HCT can all 
result in impairment of endocrine function. The most 
significant endocrine complications are associated with 
exposure to radiation and chemotherapeutic agents 
(eg,, busulfan), chronic GVHD, and prolonged corti-
costeroid exposure.63 
Subclinical, compensated hypothyroidism, with el-
evated TSH and normal serum free T4 levels, occurs 
in 7-15% of patients in the first year after transplanta-
tion. The reported incidence of frank hypothyroidism is 
variable depending upon risk factors in the population 
studied. Single-dose ablative TBI is associated with a 
50% incidence of overt hypothyroidism, whereas frac-
tionated TBI is associated with an incidence of about 
15%. The incidence reported after busulfan and cyclo-
phosphamide conditioning is 11%. Treatments given 
before transplantation likely also contribute to the risk 
of thyroid abnormalities. The median time to diagnosis 
of hypothyroidism is nearly 4 years after HCT or TBI 
exposure. When TSH is elevated with normal T4 levels, 
assessment should be repeated in 2 months, or therapy 
should be initiated at the discretion of the treating phy-
sician. Patients who start thyroid hormone replacement 
should be reassessed at about 6 weeks after initiation 
of therapy. Further individual dose adjustment should 
be based on periodic thyroid assessment, most often 
recommended at 6-month intervals. Autoimmune thy-
roiditis may also occur following radiation. Radiation to 
the neck and total body irradiation has been associated 
with dose-related increases in risk of thyroid malignan-
cy, often with long latent periods.64
 Gonadal dysfunction is highly prevalent in HCT 
recipients, with rates as high as 92% for males and 99% 
for females. The degree of dysfunction is dependent on 
age, gender, pre-transplant therapy, and conditioning 
regimen.65 Although the risk of gonadal failure is high 
in all individuals, women generally experience higher 
rates of failure than do men. 
Women are at high risk of hypergonadotropic hy-
pogonadism after HCT.66 Hypogonadism is nearly 
universal after high dose irradiation or busulfan. Risk 
is lower with cyclophosphamide alone. In general, ovar-
ian endocrine failure is irreversible in adult women, but 
younger women, particularly prepubescent girls, have a 
better opportunity for recovery of gonadal function.
Fractionation of radiation reduces the risk com-
pared with unfractionated radiation. Prepubertal girls 
should be monitored closely for onset of puberty and, if 
puberty is not experienced by age 12 to 13, be referred 
for full endocrinology evaluation and consideration of 
hormone supplementation. Adult women should be 
evaluated by a gynecologist and may require hormone 
replacement therapy to maintain libido, sexual function, 
and bone density. Libido is often decreased and only 
partially corrected by hormone replacement therapy in 
women. Vaginal GVHD may result in strictures and 
synechiae. Supplemental vaginal lubrication is available 
and should be discussed by the treating physician.
Most men have normal testosterone levels after 
transplantation, although germ cell damage (infertil-
ity) is a near-universal finding in men exposed to high 
doses of radiation or chemotherapy. Most reports sug-
gest that prepubertal boys experience normal puberty 
and demonstrate normal testosterone levels following 
HCT.66 Testing and consideration of hormone replace-
ment therapy for men is recommended based on symp-
toms. Failure to progress through puberty in a timely 
fashion should prompt referral for a full endocrinology 
evaluation.
Transplant recipients have a low incidence of pri-
mary adrenal failure after HCT. Chronic therapy with 
corticosteroids for GVHD will suppress the pituitary-
adrenal axis, but function usually recovers gradually 
once exogenous corticosteroid exposure ends. Greater 
length and intensity of exposure is generally associ-
ated with longer persistence of adrenal suppression. 
Patients with prolonged exposure to corticosteroids 
after HCT should have adrenal axis testing when 
withdrawing corticosteroids, particularly if symptoms 
of adrenal insufficiency develop. Clinicians should 
maintain awareness of possible hypoadrenalism in pa-
tients receiving long term corticosteroids who develop 
acute illness and consider ‘stress dose’ corticosteroids. 
Growth in children may be adversely affected by 
HCT, depending upon their pre-transplant therapy 
and conditioning regimen.65,66 A large body of data 
suggests that radiation is associated with growth de-
fects in children who receive HCT. Cranial radiation, 
in particular, increases the risk of diminished growth 
in children. Some reports suggest that chemotherapy 
alone may cause growth deficiencies. Growth is a com-
plicated process and may be adversely impacted by 
many additional factors, including general illness, nu-
tritional deficits, hormonal deficiencies, long-term cor-
special report laTe eFFeCTS guidelineS FOr HCT SurvivOrS 
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com20
ticosteroids, and GVHD. The risk of impaired growth 
is greatest in the youngest children. Children should 
be closely monitored for appropriate growth velocity 
after HCT. A pediatric endocrinologist should evalu-
ate children who do not achieve adequate growth, and 
assessment of growth hormone levels should be con-
sidered. Growth hormone deficiency following TBI 
has been demonstrated in some studies, but not in 
others. Since growth failure is likely to be multifacto-
rial, consideration must be given to causes other than 
inadequate growth hormone. The benefits of growth 
hormone supplementation are unclear. However, in 
children with demonstrated deficiency, supplementa-
tion is commonly prescribed.
Recommendations
1.  Thyroid function tests (TSH, T3, and free T4) 
should be performed at 1 year and yearly thereafter 
in all transplant recipients and additionally if rel-
evant symptoms develop.
2.  Clinical and endocrinologic gonadal assessment at 
1 year after HCT is recommended for all women 
who were post-pubertal at the time of transplanta-
tion. Frequency of subsequent assessments should 
be guided by clinical need (eg,, menopausal status). 
Women should have annual gynecologic evaluation 
as part of general health screening, at which time, 
hormone replacement therapy should be addressed 
for those who are post-menopausal. 
3.  Gonadal function in men, particularly FSH, LH, 
and testosterone, should be assessed if symptoms 
warrant (lack of libido or erectile dysfunction). 
Consider referral to an endocrinologist for men 
who may need testosterone replacement therapy. 
4.  Clinical and endocrinologic gonadal assessment of 
pre-pubertal boys and girls should be initiated 6-12 
months after transplantation, with further follow-
up schedule determined in consultation with an en-
docrinologist.
5.  Patients withdrawing from prolonged corticoste-
roid usage should have slow terminal tapering of 
corticosteroids; stress doses of corticosteroids may 
be warranted during acute illness in patients who 
have been on chronic corticosteroids in the past.
6.  Growth velocity should be monitored every year in 
all children, with assessment of thyroid function 
and growth hormone if growth velocity is abnormal.
MUCOCUTANEOUS COMPLICATIONS
Late complications involving skin and appendages are 
frequent after HCT.67 Nearly 70% of patients with 
chronic GVHD experience skin involvement. Early 
changes of lichen-planus like or papulosquamous le-
sions may progress to sclerosis or poikiloderma and can 
be associated with skin ulcers and subsequent infec-
tions. Alopecia, thinning of scalp hair, nail dystrophy, 
sweat impairment and skin dyspigmentation are com-
mon complications after chronic GVHD.
HCT survivors, especially recipients of allogeneic 
HCT, are at risk for developing secondary cancers of the 
skin.24 Patients should be counseled about early detec-
tion and prevention of skin cancers including avoiding 
excessive sun exposure, using adequate skin protection 
and periodic self examination of the skin with prompt 
referral to a dermatologist for further evaluation and 
treatment of suspicious skin lesions. 
Severe genital GVHD may develop in approximate-
ly 12% of women with or without associated systemic 
GVHD.68,69 Patients may present with excoriated or 
ulcerated mucosa, fissures, narrowing of introitus, or 
vaginal scarring and obliteration that may lead to he-
matocolpos. Initial symptoms may be mild and nonspe-
cific such as dryness, dyspareunia or post coital bleed-
ing and if not recognized they may lead to important 
sexual dysfunction. Careful questioning and examina-
tion should be performed as patients without sexual 
activity may not detect these abnormalities and sexu-
ally active patients may not disclose relevant symptoms. 
Biopsy may be needed to establish the diagnosis. Care 
should be taken when reducing systemic immunosup-
pression as reactivation of genital GVHD may occur. 
Vaginal strictures may limit the performance of rou-
tine Papanicolaou smears as well as sexual intercourse. 
Treatment of vaginal GVHD includes topical steroids, 
topical cyclosporine and vaginal dilators. Surgical inter-
vention can be used to treat severe cases. In contrast to 
chronic GVHD, patients with hypo-estrogenism due 
to premature menopause may present with thin and 
pale vulvar mucosa that responds well to lubricants and 
topical estrogens. However, patients may have changes 
due to GVHD and hypo-estrogenism concurrently. 
Genital involvement with GVHD is less common in 
men and may result in phimosis.
Recommendations
1.  Patients should perform routine self examination 
of the skin and avoid excessive exposure of sunlight 
without adequate protection. 
2.  All women recipients of allogeneic HCT should have 
clinical screening for symptoms of genital GVHD. 
Women who have established chronic GVHD 
should have gynecological exam to screen for genital 
involvement. 
3.  Patients should be counseled about self examination 
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of the vaginal area, general hygiene measures, and 
early recognition of local symptoms. Application of 
topical vaginal immunosuppressive agents, such as ul-
trahigh potency corticosteroids or calcineurin inhibi-
tors, prescription of systemic hormonal replacement 
therapy if indicated, and the use of vaginal dilatators 
should be initiated early in the course of the disease.
SECONDARY CANCERS
Second malignancies after HCT are a devastating late 
complication. Patients receiving allogeneic HCT have 
a 2 to 3 fold increased risk of developing solid tumors, 
compared to an age-, gender-, and region-adjusted pop-
ulation.59 Nearly all cancer types are described after al-
logeneic and autologous transplant, including oral can-
cers, as mentioned above. Risk factors include radiation 
therapy, length, and intensity of immunosuppression 
and chronic GVHD.26 However, a recent long-term 
follow-up analysis of patients transplanted after my-
eloablative doses of busulfan and cyclophosphamide 
found similar increased risk.25 Risk increases with time 
after transplantation, particularly for radiation-related 
malignancies. Recent analyses suggest that risk of radi-
ation-related (sarcoma, breast and thyroid cancers) and 
non-radiation related (squamous cell carcinoma linked 
to chronic GVHD) solid tumors continues to increase 
beyond 10-years post transplantation.24,26 Children 
who have received cranial irradiation are at risk for de-
veloping brain tumors. HCT recipients with Fanconi 
anemia are also at risk for developing oro-pharyngeal 
cancers. Providers can consider vaccination against hu-
man papilloma virus according to country-specific gen-
eral population recommendations.10 All patients should 
at least receive country-specific general population rec-
ommendations for screening for cancers. Screening for 
breast cancer is recommended at an earlier age (25 years 
or 8 years after radiation, whichever occurs later) but 
no later than age 40 among recipients of TBI or chest 
irradiation. Early referral to a dermatologist should be 
considered in patients with skin lesions suspicious for 
cancer. 
Risk of secondary leukemia or myelodysplasia after 
autologous HCT is also higher than anticipated, with 
an overall incidence of about 4% at 7 years after trans-
plantation; with a median onset of 2.5 years (range, 3 
months to 7 years) posttransplantation. Risk appears 
to be increased for patients receiving prior alkylator 
therapy, prolonged administration of conventional che-
motherapy, and higher doses of pre-transplant irradia-
tion.70 
Post transplant lymphoproliferative disorders 
(PTLD) are a rare complication of allogeneic HCT 
associated with greater donor-recipient HLA dispar-
ity, T cell depletion and GVHD.71 Overall incidence is 
1% at 10 years after HCT. Although these usually oc-
cur early (within 6 months of transplantation), PTLD 
is reported as late as 8 years after HCT. The majority of 
PTLD are associated with Epstein–Barr Virus (EBV) 
infection. Quantitative PCR detection of EBV reactiva-
tion allows prompt initiation of anti-CD20 monoclonal 
antibody therapy before development of frank PTLD.59
Recommendations
1.  Exposure to radiation, and photosensitizing effects 
of many commonly used transplantation-related 
medications increases the risk of skin cancers among 
HCT recipients. All HCT recipients should be en-
couraged to reduce UV skin exposure through use of 
high SPF sunscreens or skin coverage.
2.  All patients should be advised of the risks of second-
ary malignancies annually and encouraged to rou-
tinely perform recommended screening self-exami-
nation such as genital/testicular and skin examina-
tion. Women should discuss breast self-examination 
with their physicians. All patients should be encour-
aged to avoid high-risk behaviors as recommended 
under General Health and Preventive Screening sec-
tion, including avoidance of tobacco, passive tobacco 
exposure or excessive unprotected skin UV exposure.
3.  Screening clinical assessment should be performed 
yearly, and should include symptom review for sec-
ondary malignancies. Clinical examination and 
screening for secondary malignancies should follow 
the recommendations outlined under the General 
Health and Preventive Screening section. In women 
with radiation exposure (eg, TBI or radiation to the 
chest region), initiation of screening mammography 
should occur at age 25 or 8 years after radiation, 
whichever occurs later, but no later than age 40 years. 
Particular attention to oral malignancies should be 
paid to patients with previous severe chronic GVHD 
of the oral and pharyngeal mucosa. 
PSYCHOSOCIAL ADJUSTMENT AND SEXUAL 
COMPLICATIONS
Depressive symptoms and psychological distress are 
frequently observed in HCT survivors. Fatigue, anger, 
insomnia, and problems with marital relationships may 
also be seen. Pediatric patients may experience altered 
behavior patterns, changes in social habits, and changes 
in academic/school behavior. At the transition from 
acute convalescence to long-term follow-up, psychologi-
cal distress may increase rather than abate as the patient 
and his/her family must cope with changes in roles, em-
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ployment situations, and financial difficulties. Spouses 
and other caregivers may also exhibit high levels of de-
pression and psychological distress. They often report 
loneliness and low levels of perceived social support. 
Children may suffer from separation from one or both 
parents and the consequences of stress and upheaval in 
the family. At a minimum, screening for depression is 
recommended every 6-12 months after transplantation 
as per the general health maintenance section below. 
Specific tools for screening for psychosocial difficulties 
after HCT are also available and could be used with a 
similar frequency to depression screening. Sexual dys-
function occurs in a significant number of survivors and 
may be multifactorial in origin, from depression to go-
nadal hormonal deficiency. 
Recommendations
1.  A high level of vigilance for psychological symp-
toms should be maintained. Clinical assessment is 
recommended throughout the recovery period, at 6 
months, at 1 year, and at least yearly thereafter, with 
mental health professional assessment recommended 
for those with recognized deficits.
2.  Inquiry as to the level of spousal/caregiver psycho-
logical adjustment and family functioning should be 
performed at regular intervals.
3.  In adults, sexual function should be queried at 6 
months, at 1 year and yearly thereafter (also see sec-
tion on Mucocutaneous complications).
FERTILITY
Male and female HCT survivors are at risk for infertil-
ity secondary to pre-transplant and transplant related 
treatment exposures.72,73 Among transplant survivors 
of the child bearing age group, loss of fertility can be 
associated with psychological consequences that can 
affect quality of life. Conditioning regimens with TBI 
or busulfan plus cyclophosphamide can cause gonadal 
failure, although risk may be lower with regimens that 
include cyclophosphamide only. Older age at transplant 
and chronic GVHD are associated with low likelihood 
of gonadal recovery. Non-assisted natural pregnancies 
following gonadal recovery in women or in partners of 
male transplant recipients have been reported, but the 
estimated incidence is less than 15%. 
The outcome of pregnancy after transplantation is 
generally good, although women are at increased risk 
of fetal and maternal complications and posttransplant 
pregnancy should be considered a high-risk pregnan-
cy.73 The incidence of congenital anomalies is not higher 
than in the normal population and the rate of miscar-
riage is not increased. Women exposed to TBI have a 
higher than normal incidence of preterm deliveries and 
low or very low birth weight infants. Irradiation may 
result in uterine vessel damage and reduce uterine vol-
ume. 
A general recommendation is to delay spontaneous 
or assisted pregnancies for at least two years after HCT 
since this is the period of highest risk of relapse after 
transplantation. Contraception counseling in survivors 
after HCT with gonadal recovery is recommended and 
contraception is advisable if fertile or if fertility status 
is not known and pregnancy is not desired. Even if in-
fertile, barrier contraception is recommended with new 
partners to prevent sexually transmitted diseases. 
Women with gonadal recovery should also be ad-
vised about the risks of premature menopause. 
Recommendations
1.  Consider referral to appropriate specialists for pa-
tients who are contemplating a pregnancy or are hav-
ing difficulty conceiving. 
2.  Although infertility is common, patients should be 
counselled regarding birth control posttransplanta-
tion. 
GENERAL SCREENING AND PREVENTIVE 
HEALTH
In addition to transplant-specific risk factors men-
tioned above, HCT survivors face general risks found 
in the non-transplanted population. In general, trans-
plant survivors should be under the care of physicians 
comfortable with providing care for general health and 
hematology-oncology specific issues. Summarized be-
low are screening and lifestyle recommendations for the 
general adult population that are also relevant for HCT 
survivors. Further details about screening recommen-
dations for adults and children can be found at: http://
www.uspreventiveservicestaskforce.org.74,75 
Recommended screening for all patients
1.  Hypertension: Blood pressure should be checked at 
least every 2 years. In children, hypertension is de-
fined as readings greater than the 95th percentile for 
age, sex and height. Treatment is indicated for read-
ings of greater than 140/90 in adults on two separate 
visits at least 1 week apart, unless hypertension is 
mild or can be attributed to a temporary condition or 
medication (eg,, cyclosporine). Non-pharmacologic 
treatments may also be tried for mild hypertension 
and include moderate dietary sodium restriction, 
weight reduction in the obese, avoidance of excess al-
cohol intake, and regular aerobic exercise.
2.  Hypercholesterolemia: Cholesterol and HDL levels 
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should be checked every five years starting at age 35 
for men and 45 for women. Screening should start at 
age 20 for anyone who smokes, has diabetes, hyper-
tension, obesity (body mass index >30 kg/m2), or a 
family history of heart disease before age 50 for male 
relatives or before age 60 for female relatives. Fasting 
is not required for accurate measurement of choles-
terol and HDL, but is required for LDL and triglyc-
erides. As a rough guideline, total cholesterol levels 
>200 mg/dl (>5.0 mmol/l) or HDL levels <40 mg/
dl (<1 mmol/l) should be followed up by a full fast-
ing lipid panel. Treatment goals are based on overall 
risk of heart disease (eg,, greater than a 10% chance 
of coronary heart disease in 10 years). Overall risk 
assessment will include the following risk factors: 
age, sex, diabetes, clinical atherosclerotic disease, 
hypertension, family history, low HDL (<40 mg/dl 
or 1.0 mmol/l), and smoking. An online calculator 
is available at http://www.nhlbi.nih.gov/guidelines/
cholesterol/index.htm.
3.  Colorectal cancer: Screening should start at age 50 
in the absence of a family history (first degree rela-
tive diagnosed with colorectal cancer before age 60). 
The interval of testing depends on the type of testing 
procedure and the prior screening results. There are 
several screening approaches including annual fecal 
occult blood testing (3 cards at home), sigmoidosco-
py every 5 years with fecal occult testing every 3 years, 
or colonoscopy every 10 years. Virtual computerized 
tomography is a new method, currently under inves-
tigation. No one approach alone or in combination 
has proven superior, however a single digital rectal 
exam with occult blood testing is not recommended. 
4.  Diabetes: Screening for type 2 diabetes is indicated 
for people every three years after age 45 or in those 
with sustained higher blood pressure (>135/80) be-
cause blood pressure targets are lower for diabetics. 
A fasting plasma glucose > 126 mg/dl (>7 mmol/l), 
confirmed by testing on another day, is diagnostic for 
diabetes. 
5.  Depression: Asking two simple questions about 
mood and anhedonia (“Over the past 2 weeks, have 
you felt down, depressed, or hopeless?” and “Over the 
past 2 weeks, have you felt little interest or pleasure 
in doing things?”) is probably as effective as longer 
screening tools. Frequency of screening is not stated, 
but it is reasonable to screen every 6-12 month post-
transplantation or as clinically indicated. Affirmative 
answers to the questions above should trigger in 
depth evaluation for depression to determine the 
need for pharmacological or psychotherapeutic treat-
ments.
6.  Sexually transmitted diseases: Chlamydia screen-
ing is recommended for women under the age of 25 
who are sexually active. Screening and appropriate 
treatment decrease the incidence of pelvic inflamma-
tory disease and pregnancy-related complications, 
although most women will be infertile after myeloab-
lative transplantation. Male and female survivors 
should be reminded that protection against sexually 
transmitted disease is important even when pregnan-
cy is unlikely or impossible. 
Sex-specific recommendations
Recommended screening for men:
1. Prostate cancer: There is no consensus about the use 
of prostate-specific antigen or digital rectal examina-
tion for prostate cancer screening.
Recommended screening for women:
1.  Breast cancer: Screening with mammograms should 
start at age 40 and occur every 1-2 years. Breast self-
exam is not recommended. In women exposed to > 
800 cGy radiation, screening should start at age 25 
or 8 years after radiation exposure, whichever is lat-
er but no later than age 40, based on the data from 
Hodgkin lymphoma survivors.
2.  Cervical cancer: Screening with pap smears should be 
performed every 1-3 years in women older than 21 or 
within three years of initial sexual activity, whichever 
occurs earlier.
3.  Osteoporosis: Screening with a bone density test 
should start at age 65 for women in the general popu-
lation, or if the individual’s fracture risk is equivalent 
to a 65 year old woman (9.3% risk at 10 years).76 An 
online calculator is available to determine the 10 year 
risk of fracture (www.shef.ac.uk/FRAX/). Also see 
section on Skeletal Complications for additional rec-
ommendations for HCT recipients. 
Healthy lifestyle recommendations for all patients
1.  Eat a healthy diet with a wide variety of foods.
2.  Don’t smoke (passive or active exposure), chew to-
bacco or use illegal drugs. 
3.  Use alcohol in moderation, generally less than 2 
drinks per day. 
4. Maintain a healthy weight. 
5.  Avoid excessive sun exposure and wear sunscreen 
protection for anticipated periods of long exposure.
6.  Follow general population age specific guidelines for 
physical activity (www.health.gov/paguidelines).77 
Adults (aged 18-64) should do 2 hours and 30 min-
utes a week of moderate-intensity, or 1 hour and 15 
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minutes a week of vigorous-intensity aerobic physi-
cal activity or an equivalent combination of moder-
ate- and vigorous-intensity aerobic physical activity. 
Aerobic activity should be performed in episodes of 
at least 10 minutes. Adults should also do muscle 
strengthening activities that involve all major mus-
cle groups performed on 2 or more days per week. 
IMPLEMENTATION OF GUIDELINES IN 
RESOURCE LIMITED COUNTRIES
Although the Working Group has provided recom-
mendations that should be applicable to all HCT 
recipients, they recognized that resource constraints 
may limit their implementation, especially in certain 
geographic regions and developing countries. Some 
examples of such challenges include availability of 
specialists with expertise and experience in managing 
posttransplant complications and availability of tests 
and procedures. Furthermore, issues related to health-
care access (eg,, distance to transplant center or health 
care facility with adequate expertise and resources) 
may restrict the ability of some patients to obtain 
screening and preventive care. In circumstances where 
resource limitations do not allow for comprehensive 
evaluation and follow-up, health care providers should 
use their best clinical judgment in determining ap-
propriate preventive care for HCT survivors based on 
their individual exposures and risk-factors for long-
term complications. 
LONG TERM FOLLOW-UP OF HCT 
RECIPIENTS
To facilitate transition of HCT recipients from one 
phase of posttransplant care to another, transplant 
providers should provide HCT recipients with a sur-
vivorship care plan that includes a treatment summary 
and a follow-up care plan. This document can serve as 
an instrument for reminding providers about appro-
priate surveillance for late complications based on an 
individual patient’s risk-factors and exposures. Since 
survivors can be at risk for late relapse, the care plan 
should also include appropriate follow-up for the dis-
ease for which HCT was performed. Survivorship care 
plan instruments that are specific to HCT recipients 
are lacking. Until they are routinely available, providers 
can consider instruments that have been developed for 
cancer survivors in general (eg,, LIVESTRONG Care 
Plan [www.livestrongcareplan.org], Passport for Care® 
[www.txch.org/passportforcare]). In addition, provid-
ers can consider incorporating the patient version of 
these guidelines (available at www.BeTheMatch.org/
Patient) into a survivorship care plan document for 
HCT recipients. 
 Long-term survivors of HCT may not receive care 
at their transplant center. Because of patient or center 
preference, absence of immediate transplant related 
complications, or distance from the transplant center, 
transplant recipients may transition their care back to 
their hematologist-oncologists, primary care physi-
cians or other health care providers. With an increas-
ing number of transplant survivors, it is likely that 
non-transplant health care providers will play a greater 
role in survivorship care and may need to be aware of 
the unique exposures, risk factors and medical issues 
these patients face. The working group recognized 
that the models and primary site for long-term follow-
up will vary by country and available resources. On oc-
casion, adherence to particular recommendations may 
be inconsistent with national or regional guidelines, 
the availability of specific procedures or medications, 
or local epidemiological conditions. Individual clini-
cians should practice best clinical judgment in imple-
menting these guidelines and when caring for an indi-
vidual patient, should consider age, gender, coexisting 
comorbidities, cancer and transplant related exposures 
and immediate side effects in determining patient 
risks for specific long-term complications. Prevention, 
screening and management of late complications of 
transplantation may require a multidisciplinary ap-
proach, with involvement of the transplant center, on-
cologists, subspecialists, primary care physicians, and 
other health care providers, as necessary. 
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TABLE A. vaccinations recommended for both autologous and allogeneic HCT recipients (adapted from references 9-11).
Vaccine Recommended for use after HCT Time post-HCT to initiate vaccine No. of doses
a
Pneumococcal conjugate (PCv) Yes 3-6 months 3-4b
Tetanus, diphtheria,a cellular 
pertussisc Yes 6-12 months 3
d
Haemophilus influenzaee 
conjugate Yes 6-12 months 3
Meningococcal conjugate Follow country recommendations for general population 6-12 months 1
inactivated polio Yes 6-12 months 3
recombinant hepatitis B Follow country recommendations for general population 6-12 months 3
inactivated influenza Yearly 4-6 months 1-2e
Measles-mumps-rubella (live)f,g Measles: all children and seronegative adults 24 months 1-2
h
adapted from: “guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective”, Biology of Blood and Marrow 
Transplantation, volume 15, issue 10, Pages 1143-1238, Copyright 2009, with permission from elsevier; and “vaccination of hematopoietic cell transplant recipients”, Bone Marrow 
Transplantation, volume 44, issue 8, Pages 521-526, Copyright 2009, with permission from Macmillan Publishers ltd. 
guidelines for vaccinations considered optional or not recommended for HCT recipients and for vaccinations for family, close contacts and health-care workers of HCT recipients 
are available from these references. 
a a uniform specific interval between doses cannot be recommended, as various intervals have been used in studies. as a general guideline, a minimum of 1 month between 
doses may be reasonable. bFollowing the primary series of three PCv doses, a dose of the 23-valent polysaccharide pneumococcal vaccine (PPSv23) to broaden the immune 
response might be given. For patients with chronic gvHd who are likely to respond poorly to PPSv23, a fourth dose of the PCv should be considered instead of PPSv23. cdTaP 
(diphtheria tetanus pertussis vaccine) is preferred, however, if only Tdap (tetanus toxoid-reduced diphtheria-toxoid reduced acellular pertussis vaccine) is available (for example, 
because dTaP is not licensed for adults), administer Tdap. acellular pertussis vaccine is preferred, but the whole-cell pertussis vaccine should be used if it is the only pertussis 
vaccine available.dSee reference for consideration of an additional dose(s) of Tdap for older children and adults. eFor children <9 years of age, two doses are recommended 
yearly between transplant and 9 years of age. fMeasles, mumps and rubella vaccines are usually given together as a combination vaccine. in females with pregnancy potential, 
vaccination with rubella vaccine either as a single or a combination vaccine is indicated. gnot recommended <24 months post-HCT, in patients with active gvHd and in patients on 
immune suppression. hin children, two doses are favored.
APPENDICES
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TABLE B. recommendations for screening and prevention of late 
complications in long-term HCT survivors by selected exposures 
and risk-factors; this table highlights late complications that 
require greater vigilance or alternate followup schedule in this 
group of patients in addition to guidelines applicable for all HCT 
recipients (Table 1).
Tissues/organs Monitoring Tests and Preventive Measures 
Pediatric HCT recipients
Oral Yearly assessment of teeth development
nervous system annual assessment for congnitive development milestones
endocrine
-  Clinical and endocrinologic gonadal 
assessment for pre-pubertal boys 
and girls within 1 year of transplant, 
with further followup as determined 
in consultation with a pediatric 
endocrinologist
-  Monitor growth velocity annually; 
assessment of thyroid, and growth 
hormone function if clinically indicated 
Patients with active or history of chronic GVHD
immune system
-  antimicrobial prophylaxis targeting 
encapsulated organisms and PCP for 
the duration of immunosuppressive 
therapy 
-  Screening for CMv reactivation should 
be based on risk factors, including 
intensity of immunosuppression.
Ocular
-  routine clinical evaluation, and if 
indicated, ophthalmologic examination 
more frequently than general 
recommendations of 6 months, 1 year 
and yearly thereafter 
Oral
-  Consider more frequent oral and 
dental assesments with particular 
attention to intra-oral malignancy 
evaluation compared to general 
recommendations of 6 months, 1 year 
and yearly thereafter for clinical oral 
assessment and 1 year and yearly 
therafter for dental assessment
respiratory
-  Some experts recommend clinical 
evaluation (± PFT’s) start before 6 
months and occur more frequently 
than general recommendations of 6 
months, 1 year and yearly thereafter
Muscle and 
connective 
tissue
-  Physical therapy consultation in 
patients with prolonged corticosteroid 
exposure, fascitis or scleroderma
-  Frequent clinical evaluation by manual 
muscle tests or by assessing ability to 
go from sitting to standing position for 
patients on prolonged corticosteroids
Skeletal 
-  Some experts recommend dual 
photon densitometry at an earlier 
date in patients with prolonged 
corticosteroid or calcineurin inhibitor 
exposure compared to general 
recommendations of 1 year 
Tissues/organs Monitoring Tests and Preventive Measures 
endocrine
-  Slow terminal tapering of 
corticosteroids for those with 
prolonged exposure
-  Consider stress doses of 
corticosteroids during acute illness for 
patients who have received chronic 
corticosteroids
Mucocutaneous
-  Consider more frequent gynecologic 
evaluation based on clinical 
symptoms compared to general 
recommendations of 1 year and yearly 
thereafter
Second cancers
-  Clinical and dental evaluation with 
particular attention towards oral and 
pharyngeal cancer
-  Counsel patients about risks of 
secondary malignancies annually, 
particularly of the oro-pharynx and 
skin, and encourage them to perform 
self exam (e.g., skin)
Patients with prolonged pre- or post-transplant corticosteroid 
exposure
immune system
-  antimicrobial prophylaxis targeting 
encapsulated organisms and PCP for 
the duration of immunosuppressive 
therapy 
-  Screening for CMv reactivation should 
be based on risk factors, including 
intensity of immunosuppression.
Muscle and 
connective 
tissue
-  Physical therapy consultation 
-  Frequent clinical evaluation by manual 
muscle tests or by assessing ability to 
go from sitting to standing position
Skeletal 
-  Some experts recommend 
dual photon densitometry at an 
earlier date compared to general 
recommendations of 1 year 
endocrine
-  Slow terminal tapering of 
corticosteroids for those with 
prolonged exposure
-  Consider stress doses of 
corticosteroids during acute illness for 
patients who have received chronic 
corticosteroids
TBI recipients
Mucocutaneous
-  Consider more frequent gynecologic 
evaluation based on clinical 
symptoms compared to general 
recommendations of 1 year and yearly 
thereafter
Second cancers
-  Screening mammography in women 
starting at age 25 or 8 years after 
radiation exposure, whichever occurs 
later but no later than age 40
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TABLE C. list of guidelines referenced in this manuscript and links to their websites.
Guideline (Reference) Sponsor Website Link
long-term followup guidelines for survivors of 
childhood, adolescent and young adult cancers
 Children‘s Oncology group (COg) http://www.survivorshipguidelines.org/
guidelines for preventing infectious complications 
among hematopoietic cell transplantation recipients: 
a global perspective (9,10)
  Center for international Blood and Marrow Transplant research 
(CiBMTr), the national Marrow donor Program (nMdP), the 
european Blood and Marrow Transplant group (eBMT), the 
american Society of Blood and Marrow Transplantation (aSBMT), 
the Canadian Blood and Marrow Transplant group (CBMTg), the 
infectious diseases Society of america (idSa), the Society for 
Healthcare epidemiology of america (SHea), the association of 
Medical Microbiology and infectious diseases Canada (aMMi), 
and the Centers for disease Control and Prevention (CdC)
http://www.ncbi.nlm.nih.gov/pubmed/19747629
http://www.ncbi.nlm.nih.gov/pubmed/19861977
Prevention of infective endocarditis: guidelines from 
the american Heart association (15)
 american Hearth association (aHa) http://circ.ahajournals.org/content/116/15/1736.full.pdf 
http://my.americanheart.org/professional/Statementsguidelines/
ByTopic/Topicsd-H/endocarditis_uCM_321487_article.jsp 
Third report of the expert panel on detection, 
evaluation and treatment of high blood cholesterol in 
adults (adult Treatment Panel iii) (36)
 national Heart, lung and Blood institute (nHlBi) http://circ.ahajournals.org/content/106/25/3143.long 
http://www.nhlbi.nih.gov/guidelines/cholesterol/ 
Physical activity guidelines for americans (77)  uS department of Health and Human Services (HHS) http://www.health.gov/paguidelines/ 
recommendations for the prevention and treatment 
of glucocorticoid-induced osteoporosis (52)
 american College of rheumatology (aCr) http://www.rheumatology.org/practice/clinical/guidelines/
osteoupdate.asp 
Preventive health recommendations for adults*  uS Preventive Services Task Force (uSPSTF) http://www.uspreventiveservicestaskforce.org/adultrec.htm 
Preventive health recommendations for children and 
adolescents*
 uS Preventive Services Task Force (uSPSTF) http://www.uspreventiveservicestaskforce.org/tfchildcat.htm 
*includes guidelines for cancer screening
